Mir-200 Family Induces Mesenchymal-to-epithelial Transition (met) In Ovarian Cancer Cells by Mcdonald, John et al.
c12) United States Patent 
McDonald et al. 
(54) MIR-200 FAMILY INDUCES 
MESENCHYMAL-TO-EPITHELIAL 
TRANSITION (MET) IN OVARIAN CANCER 
CELLS 
(75) Inventors: John McDonald, Arnoldsville, GA 
(US); Nathan John Bowen, Atlanta, GA 
(US); LiJuan Wang, Smyrna, GA (US) 
(73) Assignee: Georgia Tech Research Corporation, 
Atlanta, GA (US) 
( *) Notice: Subject to any disclaimer, the term ofthis 
patent is extended or adjusted under 35 
U.S.C. 154(b) by 0 days. 
(21) Appl. No.: 13/989,312 
(22) PCT Filed: Nov. 23, 2011 
(86) PCT No.: PCT/US2011/062004 
§ 371 (c)(l), 
(2), ( 4) Date: May23, 2013 
(87) PCT Pub. No.: W02012/071492 
PCT Pub. Date: May 31, 2012 
(65) Prior Publication Data 
US 2013/0243876 Al Sep. 19, 2013 
Related U.S. Application Data 
(60) Provisional application No. 61/416,434, filed on Nov. 
23, 2010. 
(51) Int. Cl. 
A61K 48100 
A61K9/51 
A61K 45106 
A61K 311713 
A61K 3117105 
C12N 151113 
A61K9/00 
(2006.01) 
(2006.01) 
(2006.01) 
(2006.01) 
(2006.01) 
(2010.01) 
(2006.01) 
(52) U.S. Cl. 
CPC ....... A61K 3117105 (2013.01); Cl2N 23101141 
(2013.01); A61K 9151 (2013.01); A61K 45106 
(2013.01); A61K 311713 (2013.01); A61K 
915138 (2013.01); C12N 151113 (2013.01); 
A61K 9100 (2013.01) 
USPC ............................................ 514/14; 536/24.5 
( 58) Field of Classification Search 
CPC combination set(s) only. 
See application file for complete search history. 
(56) References Cited 
U.S. PATENT DOCUMENTS 
5,516,631 A 
200910163435 Al * 
2010/0088775 Al 
201110021607 Al 
201110091562 Al* 
5/1996 Frisch 
612009 Bader et al. ..................... 514/44 
4/2010 Khew-Goodall et al. 
112011 Clarke et al. 
4/2011 Lyonetal. .................... 424/491 
I lllll llllllll Ill lllll lllll lllll lllll lllll 111111111111111111111111111111111 
US008895509B2 
(10) Patent No.: US 8,895,509 B2 
Nov. 25, 2014 (45) Date of Patent: 
FOREIGN PATENT DOCUMENTS 
EP 2341145 7/2011 
WO WO 2008/036765 A2 3/2008 
WO WO 2008/138578 1112008 
WO WO 2009/036332 Al 3/2009 
WO WO 2009/097136 Al 8/2009 
WO WO 2009/100430 A2 8/2009 
WO WO 2009/143379 A2 1112009 
WO WO 2010/005741 Al 1/2010 
WO WO 2010/048123 4/2010 
WO WO 2010/056737 A2 5/2010 
WO WO 2011/088226 A2 712011 
WO WO 2011/099007 Al 8/2011 
WO WO 2011/106709 A2 9/2011 
OTHER PUBLICATIONS 
Cochrane et al. (J. Oncology 2010, 821717, pp. 1-12).* 
Park et al. (Genes Dev. 2008, vol. 22 894-907). * 
van Jaarsveldet al. (Int. J. ofBiochem & Cell Bio 2010 1282-1290).* 
Hu et al. (Gynecologic Oncology 2009, vol. 114: 457-464).* 
Bendoraite et al. "Regulation of miR-200 Family microRNAs and 
SEB Transcription Factors in Ovarian Cancer: Evidence Supporting 
a Mesothelial-to-Epithelial Transition" Gynecologic Oncology 2010, 
116(1): 117-125. 
Cochrane et al. "MicroRNA-200c Mitigates Invasiveness and 
Restores Sensitivity to Microtubule-Targeting Chemotherapeutic 
Agents" Molecular Cancer Therapeutics 2009, 8:1055-1066. 
Cochrane et al. "Loss of miR-200c: A Marker of Aggressiveness and 
Chemoresistance in Female Reproductive Cancers" Journal of 
Oncology 2010, 2010:1-12. 
Dickerson et al. "Chemosensitization of Cancer Cells by siRNA 
Using Targeted Nanogel Delivery" BMC Cancer 2010, 10(10):1-11. 
Frenster et al. "Reprogramming the Human Cancer Cell Nucleus" 
Genome Biology 2010, ll(Suppl l):Pl4. 
Frisch. "Reprogramming Breast Cancer Epithelial Cells" California 
Breast Cancer Research Program 1997 (Abstract and Final Report) ( 1 
page). 
Gregory et al. "The miR-200 Family and miR-205 Regulate 
Epithelial to Mesenchymal Transition by Targeting ZEBl and SIPl" 
Nature Cell Biology 2008, 10(5):593-601 ((Supplementary Informa-
tion pp. 1-7). 
Gregory et al. "MicroRNAs Regulators of Epithelial-mesenchymal 
Transition" Cell Cycle 2008, 7(20):3112-3117. 
Hu et al. "A miR-200 microRNA Cluster as Prognostic Marker in 
Advanced Ovarian Cancer" Gynecologic Oncology 2009, 114:457-
464. 
(Continued) 
Primary Examiner - Kimberly Chong 
(74) Attorney, Agent, or Firm - Myers Bigel Sibley & 
Sajovec, PA 
(57) ABSTRACT 
The present invention provides a method of treating an ova-
rian cancer, the method comprising delivering one or more 
miR-200 family members to a mammalian subject in need 
thereof in an amount effective to treat the ovarian cancer. Also 
provided are methods of preventing metastasis of an ovarian 
cancer, the method comprising delivering one or more miR-
200 family members to a mammalian subject in need thereof 
in an amount effective to prevent metastasis. Further provided 
are methods of sensitizing an ovarian cancer to a cytotoxic 
therapy, the method comprising delivering one or more miR-
200 family members to a mammalian subject in need thereof 
in an amount effective to sensitize the ovarian cancer to the 
cytotoxic therapy. The invention also contemplates methods 
of reducing epithelial-to-mesenchymal transition (EMT) in 
an ovarian cancer or cancer cell as well as methods of induc-
ing mesenchymal-to-epithelial transition (MET). 
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MIR-200 FAMILY INDUCES 
MESENCHYMAL-TO-EPITHELIAL 
TRANSITION (MET) IN OVARIAN CANCER 
CELLS 
RELATED APPLICATION INFORMATION 
This application is a 35 U.S.C. §371 national phase appli-
cation oflnternational Application Serial No. PCT/US2011/ 
062004, filed Nov. 23, 2011, which claims the benefit of U.S. 
Provisional Application No. 61/416,434, filed Nov. 23, 2010, 
the disclosures of each of which are incorporated by reference 
herein in their entireties. 
STATEMENT REGARDING ELECTRONIC 
FILING OF A SEQUENCE LISTING 
A Sequence Listing in ASCII text format, submitted under 
37 C.F.R. §1,821, entitled 9844-14TS_ST25.txt, 2,469 bytes 
in size, generated on May 23, 2013 and filed via EFS-Web, is 
provided in lieu of a paper copy. This Sequence Listing is 
hereby incorporated by reference into the specification for its 
disclosures. 
FIELD OF THE INVENTION 
The present invention relates to miRNAs, in particular, the 
use ofmiRNAs to reduce epithelial-to-mesenchymal transi-
tion, to induce mesenchymal-to-epithelial transition, to treat 
ovarian cancer, to prevent metastasis of ovarian cancer and/or 
to sensitize ovarian cancer cells to cytotoxic agents. 
BACKGROUND OF THE INVENTION 
Ovarian cancer is a highly metastatic disease with the 
highest mortality rate of all gynecologic cancers, and is typi-
cally not diagnosed until advanced stages of the disease [Je-
mal et al., CA Cancer J Clin 2008, 5:71-96]. While existing 
methodologies (surgery, radiation, chemotherapy) are con-
sidered relatively effective in the treatment of primary ovarian 
tumors, most patients treated for advanced-staged disease 
will eventually suffer recurrence at metastatic sites. Metasta-
sis of ovarian and other cancers is promoted by the epithelial-
to-mesenchymal transition (EMT) of primary tumor cells 
[Ahmed et al., J Cell Physiol 2007, 21:581-8; Zavadil et al., 
Cancer Res 2008, 68:9574-7; Iwatsuki et al., Cancer Sci 
2009, 101:293-9; Thiery et al., Cell 2009, 139:871-90; Ver-
gara et al. Cancer Lett 2010, 291:59-66]. Because metastasis 
is the major cause of all cancer related deaths, there is a need 
in the art to understand the molecular basis of the EMT to 
identify targets for therapeutic intervention. 
SUMMARY OF THE INVENTION 
2 
a mesenchymal phenotype induced mesenchymal-to-epithe-
lial transition (MET) and sensitized the cells to treatment with 
a cytotoxic agent. 
Accordingly, as one aspect, the present invention provides 
a method of treating an ovarian cancer, the method compris-
ing delivering one or more miR-200 family members to a 
mammalian subject in need thereof in an amount effective to 
treat the ovarian cancer. 
The invention also provides a method of preventing 
1 o metastasis ofan ovarian cancer, the method comprising deliv-
ering one or more miR-200 family members to a manimalian 
subject in need thereof in an amount effective to prevent 
metastasis. According to this aspect, in a subject with local-
ized disease, future metastasis can be prevented. In a subject 
15 that has, or has had, metastatic disease, the invention can be 
practiced to prevent further metastasis and spread. 
As another aspect, the invention provides a method of 
sensitizing an ovarian cancer to a cytotoxic therapy (e.g., 
reducing resistance or refractoriness to a cytotoxic agent), the 
20 method comprising delivering one or more miR-200 family 
members to a mammalian subject in need thereof in an 
amount effective to sensitize the ovarian cancer to the cyto-
toxic therapy. The invention also contemplates methods of 
sensitizing an ovarian cancer cell to a cytotoxic therapy, the 
25 method comprising delivering one or more miR-200 family 
members to the ovarian cancer cell in an amount to sensitize 
the cell to the cytotoxic therapy. 
Also encompassed by the present invention is a method of 
reducing epithelial-to-mesenchymal transition in an ovarian 
30 cancer, the method comprising delivering one or more miR-
200 family members to a mammalian subject in need thereof 
in an amount effective to reduce epithelial-to-mesenchymal 
transition in the ovarian cancer. The invention can further be 
practiced to reduce epithelial-to-mesenchymal transition of 
35 an ovarian cancer cell, the method comprising delivering one 
or more miR-200 family members to an ovarian cancer cell 
(e.g., having an epithelial phenotype) in an amount effective 
to reduce epithelial-to-mesenchymal transition by the cell. 
As still a further aspect, the invention provides a method of 
40 inducing mesenchymal-to-epithelial transition in an ovarian 
cancer, the method comprising delivering one or more miR-
200 family members to a mammalian subject in need thereof 
in an amount effective to induce mesenchymal-to-epithelial 
transition in the ovarian cancer. Yet further, the invention 
45 provides a method of inducing mesenchymal-to-epithelial 
transition by an ovarian cancer cell, the method comprising 
delivering one or more miR-200 family members to an ova-
rian cancer cell (e.g., having a mesenchymal phenotype) in an 
amount effective to induce mesenchymal-to-epithelial tran-
50 sition by the cell. 
In representative embodiments, the ovarian cancer or ova-
rian cancer cell is an epithelial ovarian cancer or epithelial 
ovarian cancer cell. 
The foregoing and other aspects of the present invention 
55 will now be described in more detail in the following descrip-
tion of the invention. 
Ovarian cancer is the most lethal of all gynecological 
malignancies primarily due to the sloughing-off of highly 
metastatic cells from primary tumors and their subsequent 
spread throughout the peritoneal cavity. The epithelial-to- 60 
mesenchymal transition (EMT) of ovarian cancer cells 
located at the periphery of the primary tumor is believed to be 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIGS. lA-C. OVCAR3 and HEY cells display distinct 
morphological and molecular profiles. (A) OVCAR3 cells 
display a rounded/cobblestone, epithelial-like morphology 
while HEY cells display a more elongated morphology char-
acteristic of mesenchymal cells. (B) Expression levels of 
mRNAs encoding ZEB2, ZEB!, E-cadherin, N-cadherin, 
FNl (fibronectin) and VIM (vimentin) in HEY cells normal-
ized to mean expression levels present in OVCAR3 cells. 
a precursor to metastasis. These mesenchymal-like cells are 
only slowly dividing, or even non-dividing, and are not good 
targets for current cytotoxic therapies. The present invention 65 
is based, in part, on the discovery that over-expression of 
members of the miR-200 family in ovarian cancer cells with 
US 8,895,509 B2 
3 
Consistent with morphological differences, the mesenchymal 
markers VIM, FNl and N-cadherin are all significantly 
(*p<0.01, t-test) more highly expressed in HEY cells relative 
to OVCAR3 cells; the epithelial marker E-cadherin is 
expressed at significantly lower levels (*p<0.01) while the 
repressors of E-cadherin, ZEB 1 and ZEB 2 are expressed at 
significantly higher levels (*p<0.01) in HEY relative to 
OVCAR3 cells. (C) Consistent with the hypothesis that the 
down-regulation of members of the miRNA-200 family of 
microRNAs may contribute to EMT in ovarian cancer, miR- 10 
141, miR-429 and miR-205 are all expressed at significantly 
lower levels (*p<0.01) in HEY relative to OVCAR3 cells 
while levels of 3 microRNAs not previously implicated in 
EMT (let-7a, let-7d and miR-320) are not significantly dif- 15 
ferent between the two cell lines. The levels of mRNA shown 
in (B) and (C) were determined by qRT-PCR and the results 
reported as mean±SEM. 
FIGS. 2A-B. Overexpression of miR-429 in HEY cells 
induces morphological and molecular changes characteristic 20 
of MET. (A) Cells transfected with miR-429 displayed a 
change from an elongated mesenchymal-like morphology to 
4 
Nucleotide sequences are presented herein by single strand 
only, in the 5' to 3' direction, from left to right, unless specifi-
cally indicated otherwise. Nucleotides and amino acids are 
represented herein in the manner recommended by the 
IUPAC-IUB Biochemical Nomenclature Commission, or 
(for amino acids) by either the one-letter code, or the three 
letter code, both in accordance with 37 C.F.R. §1.822 and 
established usage. 
Unless the context indicates otherwise, it is specifically 
intended that the various features of the invention described 
herein can be used in any combination. 
Moreover, the present invention also contemplates that in 
some embodiments of the invention, any feature or combina-
tion of features set forth herein can be excluded or omitted. 
To illustrate, if the specification states that a composition 
comprises components A, B and C, it is specifically intended 
that any of A, B or C, or a combination thereof, can be omitted 
and disclaimed singularly or in any combination. As another 
example, ifthe specification states that a particular position in 
a polynucleotide can be, e.g., C, T or A, it is specifically 
intended that any of C, T, A, or a combination thereof, can be 
omitted and disclaimed singularly or in any combination. 
Unless otherwise defined, all technical and scientific terms 
used herein have the same meaning as commonly understood 
by one of ordinary skill in the art to which this invention 
belongs. The terminology used in the description of the inven-
tion herein is for the purpose of describing particular embodi-
ments only and is not intended to be limiting of the invention. 
Definitions. 
As used herein, "a," "an" or "the" can mean one or more 
than one. For example, "a" miRNA can mean a single species 
ofmiRNA or a multiplicity ofmiRNAs. 
a rounded epithelial-like morphology. No morphological 
changes were observed in cells transfected with miR-320 or 
with the negative control. (B) Relative expression of mRNAs 25 
encoding ZEB2, ZEB!, E-cadherin, N-cadherin, FNl (fi-
bronectin) and VIM (vimentin) in HEY cells after transfec-
tion with miR-429, miR-320 and a negative control as deter-
mined by qRT-PCR. The data are reported as mean±SEM, 
Concurrent with the morphological changes, levels of ZEB! 30 
and ZEB2 were significantly lower while levels ofE-cadherin 
were significantly higher (*p<0.01) in cells transfected with 
miR-429 relative to cells transfected with miR-320 or the 
negative control. No significant difference in levels ofVIM, 
FNl and N-cadherin were detected among cells transfected 
with miR-429, miR-320 or the negative control. 
Also as used herein, "and/or" refers to and encompasses 
any and all possible combinations of one or more of the 
35 associated listed items, as well as the lack of combinations 
when interpreted in the alternative ("or"). 
FIG. 3. Gene ontology (GO) analysis of the 669 genes 
displaying significant changes in expression by microarray 
profiling ofmiR-429 transfected HEY cells relative to nega-
tive control. The results demonstrated a significant enrich-
ment for genes associated with functions previously associ-
ated with EMT and metastasis. 
FIGS. 4A-C. Migration, invasion and anchorage-indepen-
dent growth characteristics of HEY cells transfected with 
miR-429. (A) HEY cells transfected with miR-429 migrated 
through pores >2-fold slower and displayed a >5-fold reduc-
tion in invasiveness than HEY cells transfected with a nega-
tive control microRNA sequence. (B) A representative micro-
scopic image (!Ox) showing increased migration into a 
wound line of HEY cells transfected with miR-429 vs HEY 
cells transfected with a negative control microRNA sequence. 
(C) The ability of HEY cells transfected with miR-429 to 
grow in soft agar (anchorage independent grow) was signifi-
cantly reduced in HEY cells transfected with miR-429 vs. 
HEY cells transfected with a negative control microRNA 
sequence. 
FIG. 5. Effect of miR-429 transfection on responsiveness 
of Hey cells to cisplatin. 
DETAILED DESCRIPTION OF THE INVENTION 
It should be appreciated that the invention can be embodied 
in different forms and should not be construed as limited to 
the embodiments set forth herein. Rather, these embodiments 
are provided so that this disclosure will be thorough and 
complete, and will fully convey the scope of the invention to 
those skilled in the art. 
The term "about," as used herein when referring to a mea-
surable value such as a dosage or time period and the like, is 
meant to encompass variations of ±20%, ± 10%, ±5%, ± 1 %, 
40 ±0.5%, or even ±0.1 % of the specified amount. 
As used herein, the transitional phrase "consisting essen-
tially of' means that the scope of a claim is to be interpreted 
to encompass the specified materials or steps recited in the 
claim, "and those that do not materially affect the basic and 
45 novel characteristic(s )" of the claimed invention. See, In re 
Herz, 537 F.2d 549, 551-52, 190 U.S.P.Q. 461, 463 (CCPA 
1976) (emphasis in the original); see also MPEP §2111.03. 
Thus, the term "consisting essentially of' when used in a 
claim or the description of this invention is not intended to be 
50 interpreted to be equivalent to "comprising." 
As used herein the terms "ovarian cancer" and "cancer of 
the ovary" are used interchangeably. In representative 
embodiments, these terms refer to "epithelial ovarian cancer" 
and "epithelial cancer of the ovary" including without limi-
55 tation the various histological subtypes (e.g., serous, 
endometrioid, mucinous and/or clear cell) as well as localized 
(e.g., stage 1) and/or metastatic (e.g., stage 2, 3 and/or 4) 
cancers. In addition, "ovarian cancer" and "cancer of the 
ovary" encompass recurrent and/or platinum-resistant or 
60 platinum-refractory ovarian cancer. Metastatic disease 
includes without limitation metastatic lesions to the perito-
neal wall, the liver, small intestine, colon, diaphragm and/or 
omentum and/or malignant ascites. 
microRNAs" ("miRNAs") are a class of non-coding RNAs 
65 that regulate gene expression and, thereby, biological pro-
cesses. miRNA are single-stranded RNA molecules that gen-
erally range in length from about 20 to about 25 nucleotides in 
US 8,895,509 B2 
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their naturally-occurring form, although shorter and longer 
miRNA have been identified. miRNA are initially transcribed 
as a primary miRNA ("pri-miRNA") that is cleaved to form 
one or more precursor miRNAs ("pre-miRNA"). The pre-
miRNA molecule has regions of self-complementarity and 
forms a stem-loop structure, and is further processed by the 
enzyme Dicer to produce the "mature" (processed) miRNA. 
As is known in the art, complete complementary is generally 
not required between the mature miRNA and the target 
mRNA sequence; however, it is also known that the "seed" 
region is generally less tolerant to alterations. 
The term "miRNA" includes the primary (pri-miRNA), 
precursor (pre-miRNA) and/or mature forms of the miRNA. 
In representative embodiments, the term does not include the 
pri-miRNA and/or pre-miRNA. The term also includes modi-
fied forms (e.g., sequence variants) ofthemiRNA (e.g., 12,3, 
4, 5, or more nucleotides that are substituted, inserted and/or 
deleted). In representative embodiments, the variant substan-
tially retains at least one biological activity of the wild-type 
miRNA. The term also includes variants that have been modi-
fied to resist degradation within a subject and/or within a cell. 
The term further includes fragments of a miRNA that sub-
stantially retain at least one biological activity of the wild-
type miRNA. By "substantially retains" at least one biologi-
cal activity of the wild-type miRNA means at least about 
50%, 60%, 70%, 80%, 90% or more of the biological activity 
of the wild-type miRNA. The one or more biological activi-
ties can include any relevant activity, including without limi-
tation, binding activity (e.g., to a target mRNA), reduction or 
inhibition of EMT, induction of MET, prevention of metasta-
sis, treating ovarian cancer, increasing the sensitivity of a 
cancer cell to a cytotoxic agent, and the like. 
The term "miRNA polynucleotide," as used herein, refers 
6 
diately contiguous to a coding sequence. The term therefore 
includes, for example, a recombinant DNA that is incorpo-
rated into a vector, into an autonomously replicating plasmid 
or virus, or into the genomic DNA of a prokaryote or eukary-
ote, or which exists as a separate molecule (e.g., a cDNA or a 
genomic DNA fragment produced by PCR or restriction 
endonuclease treatment), independent of other sequences. It 
also includes a recombinant DNA that is part of a hybrid 
nucleic acid or polypeptide encoding an additional polypep-
10 tide or peptide sequence. In representative embodiments, the 
"isolated" nucleic acid or polypeptide that is substantially 
free of cellular material, viral material, and/or culture 
medium (when produced by recombinant DNA techniques), 
or chemical precursors or other chemicals (when chemically 
15 synthesized). Optionally, In representative embodiments, the 
isolated nucleic acid or polynucleotide is at least about 10%, 
20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or more 
pure. 
The term "fragment," as applied to a nucleic acid or poly-
20 nucleotide, will be understood to mean a nucleotide sequence 
of reduced length relative to a reference nucleotide sequence 
and comprising, consisting essentially of, and/or consisting 
of a nucleotide sequence of contiguous nucleotides identical 
or almost identical (e.g., 90%, 92%, 95%, 98%, 99% identi-
25 cal) to the reference nucleotide sequence. Such a fragment 
according to the invention may be, where appropriate, 
included in a larger polynucleotide of which it is a constituent. 
In some embodiments, such fragments can comprise, consist 
essentially of, and/or consist of oligonucleotides having a 
30 length ofat least about 8, 10, 12, 15, 16, 17, 18, 19, 20, 25, 30, 
35, 40, 45, 50, 75, 100, 125, 150, 200, or more. In represen-
tative embodiments, the fragment substantially retains (e.g., 
at least about 50%, 60%, 70%, 80%, 90% or more) at least one 
to a polynucleotide that is the mature miRNA, the pre-
miRNA, pri-miRNA and any other polynucleotide sequence 35 
that can be processed in a cell to produce the mature miRNA. 
activity of the full-length nucleic acid or polynucleotide. 
A "vector" is any nucleic acid molecule for the cloning of 
and/or transfer of a nucleic acid into a cell. A vector may be a 
replicon to which another nucleotide sequence may be 
attached to allow for replication of the attached nucleotide 
sequence. A "replicon" can be any genetic element (e.g., 
In representative embodiments, the term "miRNA polynucle-
otide" does not encompass the pri-miRNA and/or pre-
miRNA. 
The term "nucleic acid," "polynucleotide" or "nucleotide 
sequence" can be used interchangeably herein unless the 
context indicates otherwise. These terms encompass both 
RNA and DNA, including cDNA, genomic DNA, synthetic 
(e.g., chemically synthesized) RNA and DNA, and chimeras 
40 plasmid, phage, cosmid, chromosome, viral genome) that 
functions as an autonomous unit of nucleic acid replication in 
vivo, i.e., capable of replication under its own control. The 
term "vector" includes both viral and nonviral (e.g., plasmid) 
nucleic acid molecules for introducing a nucleic acid into a 
45 cell in vitro, ex vivo, and/or in vivo, and is optionally an 
expression vector. A large number of vectors known in the art 
may be used to manipulate, deliver and express polynucle-
otides. Vectors may be engineered to contain sequences 
encoding selectable markers that provide for the selection of 
of RNA and DNA. The nucleic acid, polynucleotide or nucle-
otide sequence may be double-stranded or single-stranded, 
and further may be synthesized using nucleotide analogs or 
derivatives (e.g., inosine or phosphorothioate nucleotides). 
Such nucleotides can be used, for example, to prepare nucleic 
acids, polynucleotides and nucleotide sequences that have 
altered base-pairing abilities or increased resistance to 
nucleases. The present invention further provides a nucleic 
acid, polynucleotide or nucleotide sequence that is the 
complement (which can be either a full complement or a 
partial complement) of a nucleic acid, polynucleotide or 55 
nucleotide sequence of the invention (e.g., encodes a nucleic 
acid, polynucleotide or nucleotide sequence comprising a 
miRNA of the invention). 
50 cells that contain the vector and/or have integrated some or all 
of the nucleic acid of the vector into the cellular genome. Such 
markers allow identification and/or selection of host cells that 
incorporate and express the proteins encoded by the marker. 
A "recombinant" vector refers to a viral or non-viral vector 
Optionally, the nucleic acid orpolynucleotide of the inven-
tion is "isolated." An "isolated" nucleic acid or polynucle- 60 
otide is a nucleotide sequence (e.g., DNA or RNA) that is not 
immediately contiguous with nucleotide sequences with 
which it is immediately contiguous (one on the 5' end and one 
on the 3' end) in the naturally occurring genome of the organ-
ism from which it is derived. Thus, in one embodiment, an 65 
isolated nucleic acid orpolynucleotide includes some or all of 
the 5' non-coding (e.g., promoter) sequences that are imme-
that comprises one or more heterologous nucleotide 
sequences transgenes ), e.g., two, three, four, five or more 
heterologous nucleotide sequences. 
Viral vectors have been used in a wide variety of gene 
delivery applications in cells, as well as living animal sub-
jects. Viral vectors that can be used include, but are not limited 
to, retrovirus, lentivirus, adeno-associated virus, poxvirus, 
alphavirus, baculovirus, vaccinia virus, herpes virus, Epstein-
Barr virus, and/or adenovirus vectors. Non-viral vectors 
include, but are not limited to, plasmids, liposomes, electri-
cally charged lipids (cytofectins), nucleic acid-protein com-
plexes, and biopolymers. In addition to a nucleic acid of 
interest, a vector may also comprise one or more regulatory 
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regions, and/or selectable markers useful in selecting, mea-
suring, and monitoring nucleic acid transfer results (delivery 
to specific tissues, duration of expression, etc.). 
By the term "express" or "expression" of a polynucleotide 
sequence, it is meant that the sequence is transcribed, and 
optionally, translated. As is understood in the art, miRNA are 
non-translated RNA sequences. 
"Effective amount" as used herein refers to an amount of a 
miRNA, vector, nucleic acid, polynucleotide, composition or 
formulation (e.g., liposome or nanoparticle) of the invention 10 
that is sufficient to produce a desired effect, which can be a 
therapeutic and/or beneficial effect. The effective amount will 
vary with the age, general condition of the subject, the sever-
ity of the condition being treated, the particular agent admin- 15 
istered, the duration of the treatment, the nature of any con-
current treatment, the pharmaceutically acceptable carrier 
used, and like factors within the knowledge and expertise of 
those skilled in the art. As appropriate, an "effective amount" 
in any individual case can be determined by one of ordinary 20 
skill in the art by reference to the pertinent texts and literature 
and/or by using routine experimentation. 
By the term "treat," "treating" or "treatment of' (and gram-
matical variations thereof) it is meant that the severity of the 
subject's condition is reduced, at least partially improved or 25 
ameliorated and/or that some alleviation, mitigation or 
decrease in at least one clinical symptom is achieved and/or 
there is a delay in the progression of the disease or disorder. In 
representative embodiments, the term "treat,", "treating" or 
"treatment of' (and grammatical variations thereof) refer to a 30 
reduction in the severity of cancer, a delay in the progression 
of the cancer, a delay in recurrence of the cancer, a reduction 
in metastatic lesions, an increased progression free survival 
period and/or an increased overall survival. 
A "treatment effective" amount as used herein is an amount 35 
that is sufficient to treat (as defined herein) the subject. Those 
skilled in the art will appreciate that the therapeutic effects 
need not be complete or curative, as long as some benefit is 
provided to the subject. 
The term "prevent," "preventing" or "prevention of' (and 40 
grammatical variations thereof) refer to prevention and/or 
delay of the onset and/or progression of a disease, disorder 
and/or a clinical symptom(s) in a subject and/or a reduction in 
the severity of the onset and/or progression of the disease, 
disorder and/or clinical symptom(s) relative to what would 45 
occur in the absence of the methods of the invention. In 
8 
As used herein, the terms "reduce," "reduces," "reduction" 
and similar terms mean a decrease of at least about 25%, 35%, 
50%, 7 5%, 80%, 85%, 90%, 95%, 97% or more. In particular 
embodiments, the reduction results in no or essentially no 
(i.e., an insignificant amount, e.g., less than about 10% or 
even 5%) detectable activity or cancer. 
As used herein, the terms "increase," "increases," "increas-
ing" and similar terms indicate an elevation of at least about 
25%, 50%, 75%, 100%, 150%, 200%, 300%, 400%, 500% or 
more. 
The term "epithelial phenotype" is understood in the art, 
and can be identified by morphological, molecular and/or 
functional characteristics. For example, epithelial cells gen-
erally have a rounded or cobblestone appearance, express the 
epithelial marker E-cadherin, are rapidly dividing and/or have 
relatively low levels of motility, invasiveness and/or anchor-
age-independent growth as compared with mesenchymal 
cells. 
The term "mesenchymal phenotype" is understood in the 
art, and can be identified by morphological, molecular and/or 
functional characteristics. For example, mesenchymal cells 
generally have an elongated or spindle-shaped appearance, 
express the mesenchymal markers vimentin, fibronectin and 
N-cadherin, divide slowly or are non-dividing and/or have 
relatively high levels of motility, invasiveness and/or anchor-
age-independent growth as compared with epithelial cells. 
The term "epithelial-to-mesenchymal transition" ("EMT") 
is known in the art and refers to a process whereby epithelial 
cancer cells take on a mesenchymal phenotype, which is 
believed to be associated with metastasis. In addition, while 
not wishing to be limited by any theory, these mesenchymal 
cells generally display reduced adhesiveness, increased 
motility and invasiveness and are relatively resistant to che-
motherapeutic agents and/or radiation (e.g., treatments that 
target rapidly dividing cells). 
Theterm "mesenchymal-to-epithelial transition" ("MET") 
is also known in the art and refers to the reprogramming of 
cells that have undergone EMT to regain one or more epithe-
lial characteristics (e.g., as described above). For example, 
such cells typically exhibit reduced motility and/or invasive-
ness and/or are rapidly dividing, and may thereby regain 
sensitivity to cytotoxic agents. 
A "subject" of the invention includes any animal suscep-
tible to ovarian cancer. Such a subject is generally a mamma-
lian subject (e.g., a laboratory animal such as a rat, mouse, 
guinea pig, rabbit, primates, etc.), a farm or commercial ani-
mal (e.g., a cow, horse, goat, donkey, sheep, etc.), or a domes-
tic animal (e.g., cat, dog, ferret, etc.). In particular embodi-
ments, the subject is a primate subject, a non-human primate 
50 subject (e.g., a chimpanzee, baboon, monkey, gorilla, etc.) or 
a human. Subjects of the invention can be a subject known or 
believed to be at risk of ovarian cancer. In representative 
embodiments, the subject is a subject that has or has had 
representative embodiments, the term "prevent,", "prevent-
ing" or "prevention of' (and grammatical variations thereof) 
refer to prevention and/or delay of the onset and/or progres-
sion of the cancer, a delay and/or reduction in recurrence of 
the cancer and/or a reduction in the onset and/or extent of 
metastasis. The prevention can be complete, e.g., the total 
absence of the disease, disorder and/or clinical symptom(s). 
The prevention can also be partial, such that the occurrence of 
the disease, disorder and/or clinical symptom(s) in the subject 55 
and/or the severity of onset and/or the progression is less than 
what would occur in the absence of the present invention. 
"Prevention" of metastasis can refer to a subject that has or 
has had localized disease in which the onset of metastasis is 
prevented and/or to a subject that has or has had metastatic 
disease in which further metastasis is prevented. 
A "prevention effective" amount as used herein is an 
amount that is sufficient to prevent (as defined herein) the 
disease, disorder and/or clinical symptom in the subject. 
Those skilled in the art will appreciate that the level of pre-
vention need not be complete, as long as some benefit is 
provided to the subject. 
ovarian cancer (e.g., is in remission). 
Subjects include females of any age that have, have had 
and/or or are at risk for ovarian cancer, including juvenile, 
mature and geriatric subjects. With respect to human subjects, 
in representative embodiments, the subject is generally an 
adult or geriatric subject, although teen and pre-teen girls 
60 have been diagnosed with ovarian cancer. 
A "subject in need" of the methods of the invention can be 
any subject that currently has and/or has had in the past, 
ovarian cancer and/or is a subject known to be, or suspected of 
being, at risk of ovarian cancer. In embodiments of the inven-
65 ti on, a "subject in need thereof' is a subject that has or has had 
(e.g., is in remission) ovarian cancer. Optionally, the subject 
has, or appears to have, localized disease and the method is 
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practiced to prevent recurrence and/or metastasis. In other 
embodiments, the subject has, or has had, metastatic ovarian 
cancer and the method is practiced to prevent recurrence 
and/or further metastatic disease and/or to extend progression 
free survival and/or overall survival. In various embodiments, 
the subject is resistant or refractory to one or more cytotoxic 
agents (e.g., a platinum chemotherapeutic agent and/or a tax-
ane) and the invention is practiced to reduce the level of 
resistance or refractoriness to the cytotoxic agent(s) (e.g., to 
sensitize the cancer the cytotoxic agent(s)). In further 10 
embodiments, the subject has recurrent ovarian cancer, and 
the invention is practiced to treat the disease, to extend pro-
gression free survival and/or overall survival. 
In embodiments of the invention, the subject has localized 
(e.g., stage 1) ovarian cancer. In embodiments of the inven- 15 
ti on, the subject has metastatic ovarian cancer (e.g., stage 2, 3 
and/or 4). 
In embodiments of the invention, the subject is in remission 
from ovarian cancer. 
In embodiments of the invention, the subject has or has had 20 
recurrent ovarian cancer. 
10 
ments, the cancer is resistant or refractory to the cytotoxic 
agent, and by "sensitizing" the cancer, the level of resistance 
or refractoriness to the cytotoxic agent is reduced. 
By "resistant" or "refractory" it is meant that the cancer or 
cancer cell is poorly responsive or essentially non-responsive 
to the therapy (or even progresses while the subject is receiv-
ing the therapy), respectively. For example, platinum-resis-
tant ovarian cancer is sometimes defined as cancer in which a 
remission of six months or less is achieved following treat-
ment with a platinum-based chemotherapy agent, and a plati-
num refractory cancer is one in which no remission is 
achieved or the cancer progresses during treatment with a 
platinum-based agent. 
By "delivering" (and granimatical variants) a miRNA to a 
cell or subject it is meant that the miRNA is provided to the 
cell or subject directly or indirectly, e.g., the miRNA itself is 
administered to the cell or subject, a polynucleotide compris-
ing or consisting essentially of the miRNA is administered to 
the cell or subject, or a polynucleotide encoding the miRNA 
(for example, a polynucleotide comprising, consisting essen-
tially of, or consisting of the complement of the miRNA) is 
administered to the cell or subject. Further, a vector, liposome 
or nanoparticle (each as described in more detail herein) 
In embodiments of the invention, the subject's cancer is 
resistant or refractory to a cytotoxic therapy, e.g., chemo-
therapy and/or radiation therapy. In embodiments of the 
invention, the subject is resistant or refractory to a platinum-
based chemotherapy agent (e.g., carboplatin, cisplatin and/or 
oxaliplatin), a taxane (e.g., taxol, paclitaxel albumin-bound 
particles [ ABRAXANE®], a nucleotide analog (e.g., gemcit-
abine ), a topoisomerase I inhibitor (e.g., a camptothecin ana-
logue such as irinotecan or topotecan), a topoisomerase II 
inhibitor (e.g., etoposide [VP-16]) and/or DNA intercalators 
such as doxorubicin (e.g., ADRIAMYCIN®, DOXIL®). 
25 comprising or encoding any of the foregoing can be admin-
istered to the cell or subject. 
By "administered" or "administration" (and other gram-
matical variants) is meant that the indicated miRNA, poly-
nucleotide, vector, liposome, nanoparticle, and the like is 
A "cytotoxic" therapy or agent is one that induces cell 
death (as opposed to a cytostatic therapy) and includes che-
motherapy and/or radiation therapy. Cytotoxic chemotherapy 
agents include without limitation a platinum-based chemo-
therapy agent (e.g., carboplatin, cisplatin and/or oxaliplatin), 
30 directly administered to the subject. For example, if a mature 
miRNA is "administered" or "directly administered" to the 
subject, it is intended that the mature miRNA itself is given or 
administered to the subject, rather than a precursor molecule 
that is processed to provide the mature miRNA or a poly-
35 nucleotide that encodes the mature miRNA. "Administra-
a taxane (e.g., taxol, paclitaxel albumin-bound particles 
[ABRAXANE®], a nucleotide analog (e.g., gemcitabine), a 
topoisomerase I inhibitor (e.g., a camptothecin analogue such 40 
as irinotecan or topotecan), a topoisomerase II inhibitor (e.g., 
etoposide [VP-16]) and/or a DNA intercalator such as doxo-
rubicin (e.g., ADRIAMYCIN®, DOXIL®). Cytotoxic thera-
pies and agents also include DNA damaging agents, e.g., an 
agent that damages DNA and, consequently, induces apopto- 45 
sis. Examples of DNA damaging agents include, but are not 
limited to, alkylating agents (e.g., cisplatin, carboplatin, ifos-
famide, chlorambucil, busulfan and thiotepa), doxorubicin, 
etoposide, mitomycin C, cisplatin, etoposide and radiation 
therapy. Particular immune therapies (e.g., monoclonal anti- 50 
bodies) may also be cytotoxic. Cytotoxic therapies are gen-
erally more effective on cells with an epithelial phenotype 
(e.g., rapidly dividing) as opposed to cells with mesenchymal 
phenotype (e.g., slowly dividing or non-dividing). Without 
wishing to be limited to any theory of the invention, in rep- 55 
resentative embodiments, the present invention induces mes-
enchymal-to-epithelial transition (MET) thereby sensitizing 
cancer cells to a cytotoxic agent. 
By "sensitizing" a cancer or a cancer cell (e.g., a cancer 
stem cell and/or a cancer cell with a mesenchymal phenotype) 60 
to a cytotoxic therapy or "increasing the sensitivity" of a 
cancer or cancer cell to a cytotoxic therapy it is meant that 
lower dosages of the cytotoxic agent are effective to treat the 
cancer or kill the cancer cell and/or the cancer or cancer cell 
tion" or "direct administration" encompasses the possibility 
that the indicated miRNA, polynucleotide, vector, etc. is 
administered by a nanoparticle, a liposome, or other delivery 
system. 
miR-200 Family Members. 
The term "miR-200 family member" refers to a miRNA in 
the miR-200 family, which currently includes miR-200a, 
miR-200b, miR-200c, miR-141 and miR-429. These miR-
NAs are encoded in two clusters in the human genome: miR-
200a, miR-200b and miR-429 are generated as a polycis-
tronic transcript from human chromosome 1, and miR-141 
and miR-200c as a single transcript from chromosome 12. 
Unless indicated otherwise, the term also includes the pri-
mary (pri-miRNA), precursor (pre-miRNA) and/or mature 
forms of these miRNAs. In representative embodiments, the 
term does not include the pri-miRNA and/or pre-miRNA. The 
term also includes modified forms (e.g., sequence variants) of 
members of the miR-200 family (e.g., 1 2, 3, 4, 5, or more 
nucleotides that are substituted, inserted and/or deleted). In 
representative embodiments, the variant substantially retains 
at least one biological activity of the wild-type miRNA. The 
term also includes variants that have been modified to resist 
degradation within a subject and/or within a cell. The term 
further includes fragments of a miR-200 family member that 
substantially retain at least one biological activity of the wild-
type mi-RNA. By "substantially retains" at least one biologi-
cal activity of the wild-type miRNA means at least about 
50%, 60%, 70%, 80%, 90% or more of the biological activity 
of the wild-type miRNA. The one or more biological activi-
is more responsive to the same dosage of the cytotoxic agent 
as compared with the response in the absence of the methods 
and compositions of the invention. In representative embodi-
65 ties can include any relevant activity, including without limi-
tation, binding activity (e.g., to a target mRNA), reduction or 
inhibition of EMT, induction of MET, prevention of metasta-
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sis, treating ovarian cancer, increasing the sensitivity of a 
cancer cell to a cytotoxic agent, and the like. 
Unless indicated otherwise, the miR-200 family member 
can be from any animal species (including sequence variants, 
fragments, primary, precursor and mature forms as discussed 
12 
3, 4, 5 or more nucleotides that are substituted, inserted and/or 
deleted outside of the seed region, but the seed region is not 
modified. 
Thus, for example, with particular respect to miR-429, a 
modified form thereof might contain 1, 2, 3, 4, 5 or more of the 
following nucleotides changes, with no modifications in the 
seed sequence: 
The "U" at position 1 ofmiR-429 can be replaced by anA, 
C and/or G and/or can be deleted. 
The "U" at position 9 ofmiR-429 can be replaced by anA, 
C and/or G and/or can be deleted. 
The "C" at position 10 of miR-429 can be replaced by an A, 
G and/or U and/or can be deleted. 
The "U" at position 11 of miR-429 can be replaced by an A, 
C and/or G and/or can be deleted. 
The "G" at position 12 of miR-429 can be replaced by an A, 
C and/or U and/or can be deleted. 
in the preceding paragraph). In representative embodiments, 
the miR-200 family member is a mammalian miR-200 family 
member, optionally ahumanmiR-200 family member (which 
can be designated by the prefix "hsa"), which would encom-
pass modified forms and fragments thereof as discussed 10 
above. The nucleotide sequences of miR-200 family mem-
bers are known in the art (e.g., in the miRBase database or 
NCBI database). For example, the nucleotide sequence of the 
pre-mRNA can be found as follows: pre-miR-141 (NCBI 
Accession No. NR_029682), pre-miR-200a (NCBI Acces- 15 
sion No. NR_029834), pre-miR-200b (NCBI Accession No. 
NR_029639), pre-miR-200c (NCBI Accession No. 
NR_029779), and pre-miR-429 (NCBI Accession No. 
NR_029957). See also, the mature and seed sequences for 
the miR-200 family members in Uhlmann et al., Oncogene 
2010; 29, 4297-4306). 
The "G" at position 13 of miR-429 can be replaced by an A, 
20 C and/or U and/or can be deleted. 
The precursor, mature and seed sequences of the human 
miR-200 (hsa-miR-200) family members is shown below in 
Table 1. 
The "U" at position 14 of miR-429 can be replaced by an A, 
C and/or G and/or can be deleted. 
The "A" at position 15 of miR-429 can be replaced by a C, 
G and/or U and/or can be deleted. 
hsa-miR-200 
Family Member Precursor miRNA 
Mature miRNA (with seed 
region underlined) 
miR-200b 
miR-200c 
miR-42 9 
miR-141 
miR-200a 
CCAGCUCGGGCAGCCGUGGCC UAAUACUGCCUGGUAAUGAUGA 
AUCUUACUGGGCAGCAUUGGA (SEQ ID NO, 2) 
UGGAGUCAGGUCUCUAAUACU 
GCCUGGUAAUGAUGACGGCGG 
AGCCCUGCACG 
(SEQ ID NO, 1) 
CCCUCGUCUUACCCAGCAGUG UAAUACUGCCGGGUAAUGAUGGA 
UUUGGGUGCGGUUGGGAGUCU (SEQ ID NO, 4) 
CUAAUACUGCCGGGUAAUGAU 
GGAGG 
(SEQ ID NO, 3) 
CGCCGGCCGAUGGGCGUCUUA UAAUACUGUCUGGUAAAACCGU 
CCAGACAUGGUUAGACCUGGC (SEQ ID NO, 6) 
CCUCUGUCUAAUACUGUCUGG 
UAAAACCGUCCAUCCGCUGC 
(SEQ ID NO, 5) 
CGGCCGGCCCUGGGUCCAUCU UAACACUGUCUGGUAAAGAUGG 
UCCAGUACAGUGUUGGAUGGU (SEQ ID NO, 8) 
CUAAUUGUGAAGCUCCUAACA 
CUGUCUGGUAAAGAUGGCUCC 
CGGGUGGGUUC 
(SEQ ID NO, 7) 
CCGGGCCCCUGUGAGCAUCUU UAACACUGUCUGGUAACGAUGU 
ACCGGACAGUGCUGGAUUUCC (SEQ ID NO, 10) 
CAGCUUGACUCUAACACUGUC 
UGGUAACGAUGUUCAAAGGUG 
ACCCGC 
(SEQ ID NO, 9) 
The miR-200 family members can also be classified based 
on the "seed" sequence. miR-200b, miR-200c and miR-429 
share the seed sequence AAUACUG, whereas miR-141 and 
miR-200a share the seed sequence AACACUG. In represen-
tative embodiments, a modified miR-200b, miR200c or miR-
429 of the invention (including fragments) comprises the seed 
sequence AAUACUG. In representative embodiments, a 
modified miR-141 or miR-200a of the invention (including 
fragments) comprises the seed sequence AACACUG. 
According to these embodiments, the miRNA can have 1, 2, 
The "A" at position 16 of miR-429 can be replaced by a C, 
G and/or U and/or can be deleted. 
The "A" at position 17 of miR-429 can be replaced by a C, 
60 G and/or U and/or can be deleted. 
The "A" at position 18 of miR-429 can be replaced by a C, 
G and/or U and/or can be deleted. 
The "C" at position 19 of miR-429 can be replaced by an A, 
65 G and/or U and/or can be deleted. 
The "C" at position 20 of miR-429 can be replaced by an A, 
G and/or U and/or can be deleted. 
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The "G" at position 21 of miR-4 29 can be replaced by an A, 
C and/or U and/or can be deleted. 
The "U" at position 22 of miR-429 can be replaced by an A, 
C and/or G and/or can be deleted. 
In embodiments of the invention, the miR-200 family 
member comprises, consists essentially of, or consists of the 
pre-miR-141, pre-miR-200a, pre-miR-200b, pre-miR-200c 
and/or pre-miR-429. 
In embodiments of the invention, the miR-200 family 
member comprises, consists essentially of, or consists of the 10 
human pre-miR-141 (SEQ ID N0:7), pre-miR-200a (SEQ ID 
N0:9), pre-miR-200b (SEQ ID NO:l), pre-miR-200c (SEQ 
ID N0:3) and/or pre-miR-429 (SEQ ID N0:5). 
14 
Alternatively, the microRNA can be produced using an 
expression vector into which a nucleic acid encoding the 
microRNA has been cloned. 
The microRNAs of the invention can be delivered directly 
into a cell by any method known in the art, e.g., by transfec-
tion, microinjection and/or a nanoparticle delivery system. In 
representative embodiments, the pre-miRNA, the pre-
miRNA and/or the mature miRNA can be administered to a 
cell. Alternately, a polynucleotide comprising or consisting 
essentially of the pri-miRNA, pre-miRNA and/or mature 
miRNA can be administered to the subject, which can option-
ally be processed to provide the mature miRNA. In other 
embodiments, the miRNA can be delivered to a subject in the 
form ofa polynucleotide (e.g., a delivery vector) that encodes 
and expresses a mRNA within the cells of the subject. 
In embodiments of the invention, the miR-200 family 
member comprises, consists essentially of, or consists of the 15 
mature miR-141, miR-200a, miR-200b, miR-200c and/or 
miR-429. Those skilled in the art will appreciate that the polynucle-
otides encoding the miRNAs of the invention will typically be 
associated with appropriate expression control sequences, 
20 e.g., transcription/translation control signals and polyadeny-
lation signals. 
In embodiments of the invention, the miR-200 family 
member comprises, consists essentially of, or consists of the 
maturehumanmiR-141 (SEQ IDN0:8), miR-200a (SEQ ID 
NO:lO), miR-200b (SEQ ID N0:2), miR-200c (SEQ ID 
N0:4) and/or miR-429 (SEQ ID N0:6). In representative embodiments, the isolated polynucle-
otide encoding the miRNA is incorporated into an expression 
vector. Expression vectors compatible with various host cells 
25 are well known in the art and contain suitable elements for 
A micro RNA can be constructed using chemical synthesis 
and enzymatic ligation reactions by procedures known in the 
art. For example, a microRNA can be chemically synthesized 
using naturally occurring nucleotides or various modified 
nucleotides designed to increase the biological stability of the 
molecules or to increase the physical stability of the duplex 
formed between the microRNA and target nucleotide 
sequences, e.g., phosphorothioate derivatives and acridine 30 
substituted nucleotides can be used. Examples of modified 
nucleotides which can be used to generate the microRNA 
include, but are not limited to, 5-fluorouracil, 5-bromouracil, 
5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-ace-
tylcytosine, 5-( carboxyhydroxylmethyl) uracil, 5-carboxym- 35 
ethylaminomethy 1-2-thiouridine, 5-carboxymethylami-
nomet-hyluracil, dihydrouracil, beta-D-galactosylqueosine, 
inosine, N6-isopentenyladenine, 1-methylguanine, 1-meth-
ylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-meth-
ylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 40 
7 -methy !guanine, 5-methy laminomethy !uracil, 5-meth-
oxyaminomethy l-2-thiouracil, beta-D-mannosylqueosine, 
5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-meth-
ylthio-N6-isopenten-yladenine, uracil-5-oxyacetic acid (v), 
wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-me- 45 
thyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, 
uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid 
(v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypro-
pyl)uracil, (acp3)w, and 2,6-diaminopurine. 
The microRNA can further include nucleotide sequences 50 
wherein at least one, or all, of the internucleotide bridging 
phosphate residues are modified phosphates, such as methyl 
phosphonates, methyl phosphonothioates, phosphoromor-
pholidates, phosphoropiperazidates and phosphoramidates. 
For example, every other one of the internucleotide bridging 55 
phosphate residues can be modified as described. In another 
non-limiting example, the microRNA is a nucleotide 
sequence in which one, or all, of the nucleotides contain a 2' 
lower alkyl moiety (e.g., C1 -C4 , linear or branched, saturated 
or unsaturated alkyl, such as methyl, ethyl, ethenyl, propyl, 60 
1-propenyl, 2-propenyl, and isopropyl). For example, every 
otherone of the nucleotides can be modified as described. See 
also, Purdon et al., Nucleic Acids Res. 17:9193 (1989); 
Agrawal et al., Proc. Natl. Acad. Sci. USA 87:1401 (1990); 
Baker et al., Nucleic Acids Res. 18:3537 (1990); Sproat et al., 65 
Nucleic Acids Res. 17 :33 73 (1989); Walder and Walder, Proc. 
Natl. Acad. Sci. USA 85:5011 (1988)). 
transcription and translation of nucleic acids. Typically, an 
expression vector contains an "expression cassette," which 
includes, in the 5' to 3' direction, a promoter, a coding 
sequence encoding a miRNA operatively associated with the 
promoter, and, optionally, a termination sequence including a 
stop signal for RNA polymerase and a polyadenylation signal 
for polyadenylase. 
It will further be appreciated that a variety of promoter/ 
enhancer elements can be used depending on the level and 
tissue-specific expression desired. The promoter can be con-
stitutive or inducible, depending on the pattern of expression 
desired. The promoter can be native or foreign and can be a 
natural or a synthetic sequence. By foreign, it is intended that 
the transcriptional initiation region is not found in the wild-
type host into which the transcriptional initiation region is 
introduced. The promoter is chosen so that it will function in 
the target cell(s) of interest. 
To illustrate, the coding sequence can be operatively asso-
ciated with an animal or mammalian promoter, including 
without limitation a cytomegalovirus (CMV) major immedi-
ate-early promoter, an albumin promoter, an Elongation Fac-
tor 1-a (EFl-a) promoter, a PyKpromoter, a MFG promoter, 
the SV 40 early (SV 40e) promoter region, the promoter con-
tained in the 3' long terminal repeat (LTR) of Rous sarcoma 
virus (RSV), the promoters of the El A or major late promoter 
(MLP) genes of adenoviruses (Ad), the herpes simplex virus 
(HSY) thymidine kinase (TK) promoter, baculovirus IEl pro-
moter, phosphoglycerate kinase (PGK) promoter, ubiquitin 
(Ube) promoter, the regulatory sequences of the mouse met-
allothionein-L promoter and transcriptional control regions, 
the ubiquitous promoters (HPRT, vimentin, a-actin, tubulin 
and the like), the promoters of the intermediate filaments 
( desmin, neurofilaments, keratin, GF AP, and the like), the 
promoters of therapeutic genes (of the MDR, CFTR or factor 
VIII type, and the like), and pathogenesis and/or disease-
related promoters. 
Other non-limiting examples of promoters include, but are 
not limited to, CYCl, HIS3, GALI, GAL4, GALlO,ADHl, 
PGK, PH05, GAPDH, ADCl, TRPl, URA3, LEU2, ENO, 
TPI, and alkaline phosphatase promoters (useful for expres-
sion in Saccharomyces); AOXl promoter (useful for expres-
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sioninPichia); and the ~-lactamase, lac, ara, tet, trp, IPD IPR, 
T7, tac, and trc promoters (useful for expression in Escheri-
chia coli). 
Inducible promoter/enhancer elements include hormone-
inducible and metal-inducible elements, and other promoters 
regulated by exogenously supplied compounds, including 
without limitation, the zinc-inducible metallothionein (MT) 
promoter; the dexamethasone (Dex)-inducible mouse mam-
mary tumor virus (MMTV) promoter; the T7 polymerase 
promoter system (see WO 98/10088); the ecdysone insect 
promoter (No et al., Proc. Natl. Acad. Sci. USA 93:3346 
(1996)); the tetracycline-repressible system (Gossen et al., 
Proc. Natl. Acad. Sci. USA 89:5547 (1992)); the tetracycline-
inducible system (Gossen et al., Science 268: 1766 (1995); see 
also Harvey et al., Curr. Opin. Chem. Biol. 2:512 (1998)); the 
RU486-inducible system (Wang et al., Nat. Biotech. 15:239 
(1997); Wang et al., Gene Ther., 4:432 (1997)); and the rapa-
mycin-inducible system (Magari et al., J. Clin. Invest. 100: 
2865 (1997)). 
Other tissue-specific promoters or regulatory promoters 
include, but are not limited to, promoters that typically confer 
tissue-specific or preferred expression in ovarian cells and 
tissue, for example, the OSP-1 (Ovarian Specific Promoter 1) 
promoter, the ovary-specific PII promoter of the aromatase 
gene, and the 5' upstream regulatory sequences of the mouse 
misiir (Mullerian inhibitory substance type II receptor) gene. 
Enhancers that may be used in embodiments of the inven-
tion include but are not limited to: an SV 40 enhancer, a 
cytomegalovirus (CMV) enhancer, an elongation factor I 
(EFl) enhancer, yeast enhancers, viral gene enhancers, and 
the like. 
Termination control regions, i.e., terminator or polyadeny-
lation sequences, may be derived from various genes native to 
the preferred hosts. In some embodiments of the invention, 
the termination control region may comprise or be derived 
from a synthetic sequence, a synthetic polyadenylation sig-
nal, an SV40 late polyadenylation signal, an SV40 polyade-
nylation signal, a bovine growth hormone (BGH) polyadeny-
lation signal, viral terminator sequences, or the like. 
It will be apparent to those skilled in the art that any suitable 
vector can be used to deliver the polynucleotide to a cell or 
subject. The vector can be delivered to cells in vivo. In other 
embodiments, the vector can be delivered to cells ex vivo, and 
then cells containing the vector are delivered to the subject. 
The choice of delivery vector can be made based on a number 
16 
mechanisms used by mammalian cells for the uptake and 
intracellular transport of macromolecules. In particular 
embodiments, non-viral nucleic acid delivery systems rely on 
endocytic pathways for the uptake of the nucleic acid mol-
ecule by the targeted cell. Exemplary nucleic acid delivery 
systems ofthis type include liposomal derived systems, poly-
lysine conjugates, and artificial viral envelopes. 
In particular embodiments, plasmid vectors are used in the 
practice of the present invention. Expression can extend over 
10 many months, although the number of positive cells is typi-
cally low (Wolff et al., Science 247:247 (1989)). Cationic 
lipids have been demonstrated to aid in introduction of 
nucleic acids into some cells in culture (Feigner and Ringold, 
Nature 337:387 (1989)). One advantage of plasmid DNA is 
15 that it can be introduced into non-replicating cells. 
Expression vectors can be designed for expression of miR-
NAs in prokaryotic or eukaryotic cells. For example, miR-
NAs can be expressed in bacterial cells such as E. coli, insect 
cells (e.g., the baculovirus expression system), yeast cells, 
20 plant cells or mammalian cells. Some suitable host cells are 
discussed further in Goedde!, Gene Expression Technology: 
Methods in Enzymology 185, Academic Press, San Diego, 
Calif. (1990). Examples of bacterial vectors include, but are 
not limited to, pQE70, pQE60, pQE-9 (Qiagen), pBS, pDlO, 
25 phagescript, psiXl 74, pbluescript SK, pbsks, pNH8A, 
pNH16a, pNH18A, pNH46A (Stratagene); ptrc99a, 
pKK223-3, pKK233-3, pDR540, and pRIT5 (Pharmacia). 
Examples of vectors for expression in the yeast S. cerevisiae 
include pYepSecI (Baldari et al., EMBO J. 6:229 (1987)), 
30 pMFa (Kurjan and Herskowitz, Cell 30:933 (1982)), pJRY88 
(Schultz et al., Gene 54: 113 (1987)), and p YES2 (Invitrogen 
Corporation, San Diego, Calif.). Non-limiting examples of 
baculovirus vectors available for expression of nucleic acids 
to produce proteins in cultured insect cells (e.g., Sf 9 cells) 
35 include the pAc series (Smith et al., Mal. Cell. Biol. 3:2156 
(1983)) and the pVL series (Lucklow and Summers Virology 
170:31 (1989)). 
Examples of mammalian expression vectors include p WL-
NEO, pSV2CAT, pOG44, pXTl, pSG (Stratagene) pSVK3, 
40 PBPV, pMSG, PSVL (Pharmacia), pCDM8 (Seed, Nature 
329:840 (1987)) and pMT2PC (Kaufman et al., EMBO J. 
6: 187 (1987) ). When used in mammalian cells, the expression 
vector's control functions are often provided by viral regula-
tory elements. For example, commonly used promoters are 
45 derived from polyoma, adenovirus 2, cytomegalovirus and 
Simian Virus 40. of factors known in the art, including age and species of the 
target host, in vitro versus in vivo delivery, level and persis-
tence of expression desired, intended purpose (e.g., for 
therapy or research), the target cell or organ, route of delivery, 
size of the isolated polynucleotide, safety concerns, and the 50 
like. 
In addition to the regulatory control sequences discussed 
above, the recombinant expression vector can contain addi-
tional nucleotide sequences. For example, the recombinant 
expression vector can encode a selectable marker gene to 
identify host cells that have incorporated the vector. 
Delivery Methods. 
The present invention also encompasses methods of deliv-
ering or administering one or more miR-200 family members 
Suitable vectors include, but are not limited to, plasmid 
vectors, viral vectors (e.g., retrovirus, alphavirus; vaccinia 
virus; adenovirus, adeno-associated virus and other parvovi-
ruses, lentivirus, poxvirus, or herpes simplex virus), lipid 
vectors, poly-lysine vectors, synthetic polyamino polymer 
vectors, and the like. 
55 to a cell (in vitro, ex vivo and in vivo) or to a subject. The one 
or more miR-200 family members can be delivered or admin-
istered to the cell or subject for any reason, e.g., for research 
purposes to study the mechanism of action of the miRNA( s ), 
to modulate cell behavior in vitro or in vivo and/or for thera-
Any viral vector that is known in the art can be used in the 
present invention. Protocols for producing recombinant viral 
vectors and for using viral vectors for nucleic acid delivery 60 
can be found inAusubel et al., Current Protocols in Molecular 
Biology (GreenPublishingAssociates, Inc. and John Wiley & 
Sons, Inc., New York) and other standard laboratory manuals 
(e.g., Vectors for Gene Therapy. In: Current Protocols in 
Human Genetics. John Wiley and Sons, Inc.: 1997). 
Non-viral transfer methods can also be employed. Many 
non-viral methods of nucleic acid transfer rely on normal 
peutic purposes. 
In representative embodiments, one or more miR-200 fam-
ily members are delivered or administered to a cell or to a 
subject to reduce EMT in the cell or subject. Accordingly, in 
exemplary embodiments, the invention provides a method of 
65 reducing EMT in an ovarian cancer cell (e.g., a cell with an 
epithelial phenotype), the method comprises delivering or 
administering one or more miR-200 family members to a cell 
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in an amount effective to reduce EMT in the cell. In other 
embodiments, the invention provides a method of reducing 
EMT in an ovarian cancer, the method comprising delivering 
or administering one or more miR-200 family members to a 
mammalian subject in need thereof in an amount effective to 
reduce EMT in the ovarian cancer. 
The invention also contemplates a method of inducing 
MET in an ovarian cancer cell, the method comprising deliv-
ering or administering one or more miR-200 family members 
18 
comprise methods of detecting the presence or absence of 
mesenchymal cells as well as quantitative and semi-quanti-
tative methods. 
According to any of the inventive methods, a cytotoxic 
therapy can be administered prior to, concurrently with and/ 
or after administration of the one or more miR-200 family 
members to a subject. By "concurrently" it is meant that the 
two treatments are sufficiently close in time to have a com-
bined effect. In embodiments of the invention, the one or 
more miR-200 family members are delivered to the subject 
concurrently with and/or within about 3 hours to about 24, 48, 
72, 96, 120, 144 or 168 hours prior to administration of a 
cytotoxic therapy, within about 6 hours to about 24, 48, 72, 
96, 120, 144 or 168 hours prior to administration of a cyto-
to an ovarian cancer cell (e.g., a cell with a mesenchymal 10 
phenotype and/or an ovarian cancer stem cell) in an amount 
effective to induce MET in the cell. The invention further 
provides a method of inducing MET in an ovarian cancer, the 
method comprising delivering or administering one or more 
miR-200 family members to a manmialian subject in need 
thereof in an amount effective to induce MET in the ovarian 
15 toxic treatment, within about 12 hours to about 24, 48, 72, 96, 
120, 144 or 168 hours prior to administration of a cytotoxic 
therapy, withinabout24 hours to about 48, 72, 96, 120, 144 or 
168 hours prior to administration of a cytotoxic therapy, 
within about 36 hours to about 72, 96, 120, 144 or 168 hours 
cancer. 
The invention further provides a method of treating an 
ovarian cancer, the method comprising delivering or admin-
istering one or more miR-200 family members to a mamma-
lian subject in need thereof in an amount effective to treat the 
ovanan cancer. 
20 prior to administration of a cytotoxic therapy, within about 48 
hours to about 72, 96, 120, 144 or 168 hours prior to admin-
istration of a cytotoxic therapy, or within about 72 hours to 
about 96, 120, 144 or 168 hours prior to administration of a As another aspect, the invention provides a method of 
preventing metastasis of an ovarian cancer, the method com-
prising delivering or administering one or more miR-200 25 
family members to a manmialian subject in need thereof in an 
amount effective to prevent metastasis. 
The invention further provides a method of sensitizing an 
ovarian cancer to a cytotoxic therapy (e.g., increasing the 
sensitivity to a cytotoxic therapy), the method comprising 30 
delivering or administering one or more miR-200 family 
members to a mammalian subject in need thereof in an 
amount effective to sensitize the ovarian cancer to the cyto-
toxic therapy. Also provided is a method of sensitizing an 
ovarian cancer cell (e.g., a metastatic cell, an ovarian cancer 35 
stem cell) to a cytotoxic therapy, the method comprising 
delivering or administering one or more miR-200 family 
members to an ovarian cancer cell in an amount effective to 
sensitize the ovarian cancer cell to the cytotoxic therapy. 
While not wishing to be bound by any theory, delivering one 40 
or more miR-200 family members to the subject or cancer cell 
can be practiced to reduce and/or prevent the level of resis-
tance or refractoriness to a cytotoxic therapy. 
According to representative embodiments, any of the 
inventive methods of delivering or administering to a subject 45 
of can further comprise detecting a level of one or more 
miR-200 family members in ovarian cancer tissue from the 
subject prior to administering the one or more miR-200 fam-
ily members to the subject. The level of the miRNAs can be 
detected in a tissue sample ex vivo or in situ. For example, a 50 
tumor sample or ascites fluid can be removed from the subject 
and the level of the one or more miR-200 family members 
evaluated. Optionally, the level in the tumor sample or ascites 
can be compared with a reference value (e.g., based on the 
levels of the one or more miR-200 family member in ovarian 55 
epithelial cells), and ifthe level is below the reference value, 
the one or more miR-200 family members are delivered to the 
subject. 
The methods of the invention can further comprise detect-
ing a level of cells having a mesenchymal phenotype in ova- 60 
rian cancer tissue from the subject prior to administering the 
one or more miR-200 family members to the subject. The 
level of mesenchymal cells can be evaluated ex vivo (e.g., in 
a tumor sample or ascites) or in situ. According to this 
embodiment, if the presence of mesenchymal cells are 65 
detected, the one or more miRNAs are delivered to the sub-
ject. Methods of detecting the level of mesenchymal cells can 
cytotoxic therapy. 
In particular embodiments of the invention, more than one 
administration (e.g., two, three, four, or more administra-
tions) can be employed over a variety of time intervals (e.g., 
hourly, daily, weekly, monthly, etc.) to achieve therapeutic 
effects. 
miR-200 family members are described in detail herein. In 
embodiments of the invention, the one or more miR-200 
family members comprise or consist of miR-141, miR-200a, 
miR-200b, miR-200c, miR-205 and/ormiR-429, in any com-
bination. 
In embodiments of the invention, the one or more miR-200 
family members comprise or consist of miR-200a, miR-200b 
and/or miR-429, in any combination. For example, the one or 
more miR-200 family members can comprise or consist of (i) 
miR-200a and miR-429; or (ii) miR-200b and miR-429. 
In embodiments of the invention, the one or more miR-200 
family members comprise or consist of miR-141 and/or miR-
200c. 
In embodiments of the invention, the one or more miR-200 
family members comprise or consist of miR200b, miR200-c 
and/or miR-429. For example, the one or more miR-200 
family members can comprise or consist of (i) miR-200b and 
miR-429; or (ii) miR-200c and miR-429. 
In embodiments of the invention, the one or more miR-200 
family members comprise or consist of miR-141 and/or miR-
200a. 
In embodiments of the invention, the one or more miR-200 
family member comprise or consist ofmiR-429. 
In embodiments of the invention, the one or more miR-200 
family members do not include the combination miR-200a, 
miR-200b and miR-429. 
In embodiments of the invention, the one or more miR-200 
family members do not include miR-200a. In embodiments of 
the invention, the one or more miR-200 family members do 
not include miR-200b. In embodiments of the invention, the 
one or more miR-200 family members do not include miR-
200c. In embodiments of the invention, the one or more 
miR-200 family members do not include miR-141. 
Optionally, the one or more miR-200 family members are 
human miRNAs (e.g., a mature human miR-429). 
In further embodiments of the invention, delivering the one 
or more miR-200 family members to a cell or subject com-
prises, consists essentially of, or consists of administering the 
US 8,895,509 B2 
19 
one or more miR-200 family members as mature miRNAs. 
For example, in representative embodiments, a mature miR-
429 is directly administered to the cell or subject. 
Nucleic acids and polynucleotides may be introduced into 
the desired cells by methods known in the art, e.g., transfec-
tion, electroporation, microinjection, transduction, cell 
fusion, DEAE dextran, calcium phosphate precipitation, lipo-
fection (lysosome fusion), nanoparticle delivery systems 
(e.g., a nanogel), use of a gene gun, or a nucleic acid vector 
transporter (see, e.g., Wu et al., J. Biol. Chem. 267:963 10 
(1992); Wu et al., J. Biol. Chem. 263: 14621 (1988); and 
Hartmut et al., Canadian Patent Application No. 2,012,311, 
filed Mar. 15, 1990). 
In various embodiments, a cationic oligopeptide (e.g., 
W095/21931), peptides derived from nucleic acid binding 15 
proteins (e.g., W096/25508), and/or a cationic polymer (e.g., 
W095/21931) can be used to introduce a nucleic acid or 
polynucleotide into a cell or subject. 
It is also possible to introduce a nucleic acid or polynucle-
otide into a cell or subject as naked nucleic acid (see U.S. Pat. 20 
Nos. 5,693,622, 5,589,466 and 5,580,859). Receptor-medi-
atednucleic acid delivery approaches can also be used (Curiel 
eta!., Hum. GeneTher. 3:147 (1992); Wu eta!., J. Biol. Chem. 
262:4429 (1987)). 
20 
et al., Biochemistry 25:5500 (1986); Ho et al., J. Biol. Chem. 
262:13979 (1987); Ho etal,J. Biol. Chem. 262:13973 (1987); 
and U.S. Pat. No. 4,957,735 to Huang et al.). Enveloped viral 
vectors can be modified to deliver a nucleic acid molecule to 
a target cell by modifying or substituting an envelope protein 
such that the virus infects a specific cell type (i.e., pseudot-
yping). In adenoviral vectors, the gene encoding the attach-
ment fibers can be modified to encode a protein domain that 
binds to a cell-specific receptor. 
In addition, the targeting moiety can be, without limitation, 
an organic or inorganic molecule, a peptide, peptide mimetic, 
protein, antibody, aptamer, growth factor, enzyme, lectin, 
antigen or immunogen, virus, viral vector, receptor, ligand 
(e.g., folic acid), a toxin, a polynucleotide, carbohydrate, 
sugar, lipid, glycolipids, nucleoprotein, glycoprotein, lipo-
protein, steroid, hormone, chemoattractant, cytokine, 
chemokine, a drug, and the like. 
In embodiments of the invention, the targeting moiety is a 
peptide, e.g., a RGD peptide ligand that targets to tumor 
neovasculature. The targeting moiety can further target the 
erythropoietin-producing hepatocellular A2 (EphA2) recep-
tor. An example of such a peptide comprises, consists essen-
tially of, or consists of the amino acid sequence YSAYPDS-
VPMMSC (SEQ ID NO: 11 ). Other possibilities for targeting 
to ovarian cancer cells include an antibody (or portion 
thereof) that recognizes a cell surface protein, e.g., the mes-
enchymal markers vimentin, fibronectin or N-cadherin, the 
epithelial marker E-cadherin, or a tumor marker such as 
CA-125, HE4 or a cancer testis antigen (e.g., GAGE, MAGE, 
The miRNA(s) can be delivered to the cell or subject tran- 25 
siently or stably. For example, transient delivery or expres-
sion of the miRNA(s) can be achieved, e.g., with lipofection, 
microinjection, or nanoparticle delivery. Gene delivery vec-
tors encoding the miRNAs can be used to provide stable 
expression. 
Vector DNA can be introduced into prokaryotic or eukary-
otic cells via conventional transformation or transfection 
techniques. As used herein, the terms "transformation" and 
"transfection" refer to a variety of art-recognized techniques 
for introducing foreign nucleic acids (e.g., DNA and RNA) 
into a host cell, including, but are not limited to, calcium 
phosphate or calcium chloride co-precipitation, DEAE-dex-
tran-mediated transfection, lipofection, electroporation, 
microinjection, DNA-loaded liposomes, lipofectamine-DNA 
complexes, cell sonication, gene bombardment using high 40 
velocity microprojectiles, and viral-mediated transfection. 
Suitable methods for transforming or transfecting host cells 
can be found in Sambrook et al., Molecular Cloning: A Labo-
ratory Manual 2nd Ed. (Cold Spring Harbor, N.Y., 1989), and 
other laboratory manuals. 
30 LAGE, NY-ES0-1). Peptide or nucleic acid aptamers can 
also be used to target ovarian cancer cells. For example, 
oligonucleotides can be engineered through repeated rounds 
of in vitro selection (e.g., SELEX) to generate nucleic acid 
aptamers with high affinity for specific targets on ovarian 
If stable integration is desired, often only a small fraction 
of cells (in particular, manimalian cells) integrate the foreign 
DNA into their genome. In order to identify and select inte-
grants, a nucleic acid that encodes a selectable marker (e.g., 
resistance to antibiotics) can be introduced into the host cells 
along with the nucleic acid of interest. Preferred selectable 
markers include those that confer resistance to drugs, such as 
G418, hygromycin andmethotrexate. Nucleic acids encoding 
a selectable marker can be introduced into a host cell on the 
same vector as that comprising the nucleic acid of interest or 
can be introduced on a separate vector. Cells stably trans-
fected with the introduced nucleic acid can be identified by 
drug selection (e.g., cells that have incorporated the select-
able marker gene will survive, while the other cells die). 
According to certain embodiments, the one or more miR-
200 family members can be targeted to ovarian cancer cells in 
vivo. Methods of targeting delivery vehicles, including lipo-
somes, viral vector and nanoparticle systems are known in the 
art. For example, a liposome, nanoparticle or viral vector can 
be directed to a particular target cell or tissue by using a 
targeting agent, such as an antibody, a soluble receptor or 
ligand. Targeting liposomes are described, for example, in Ho 
35 cancer cells. 
Pharmaceutical Compositions 
As a further aspect, the invention provides pharmaceutical 
formulations, which may comprise any of the reagents dis-
cussed herein in a pharmaceutically acceptable carrier. 
By "pharmaceutically acceptable" it is meant a material 
that is not biologically or otherwise undesirable, i.e., the 
material can be administered to a subject without causing any 
undesirable biological effects such as toxicity. 
The formulations of the invention can optionally comprise 
45 medicinal agents, pharmaceutical agents, carriers, adjuvants, 
dispersing agents, diluents, and the like. 
The miRNAs and vectors encoding miRNAs of the inven-
tion can be formulated for administration in a pharmaceutical 
carrier in accordance with known techniques. See, e.g., Rem-
50 ington, The ScienceAndPractice of Pharmacy (9'h Ed. 1995). 
In the manufacture of a pharmaceutical formulation accord-
ing to the invention, the miRNA or vector (including the 
physiologically acceptable salts thereof) is typically admixed 
with, inter alia, an acceptable carrier. The carrier can be a 
55 solid or a liquid, or both, and is preferably formulated with the 
miRNA as a unit-dose formulation, for example, a tablet, 
which can contain from 0.01 or 0.5% to 95% or 99% by 
weight of the miRNA or vector. One or more miRNAs or 
vectors can be incorporated in the formulations of the inven-
60 tion, which can be prepared by any of the well-known tech-
niques of pharmacy. 
Non-limiting examples of formulations of the invention 
include those suitable for oral, rectal, buccal (e.g., sub-lin-
gual), vaginal, parenteral (e.g., subcutaneous, intramuscular 
65 including skeletal muscle, cardiac muscle, diaphragm muscle 
and smooth muscle, intradermal, intravenous, intraperito-
neal), topical (i.e., both skin and mucosa! surfaces, including 
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airway surfaces), intranasal, transdermal, intraarticular, 
intracranial, intrathecal, and inhalation administration, 
administration to the liver by intraportal delivery, as well as 
direct organ injection (e.g., into the liver, into a limb, into the 
brain or spinal cord for delivery to the central nervous system, 
into the pancreas, or into a tumor or the tissue surrounding a 
tumor). The most suitable route in any given case will depend 
on the nature and severity of the condition being treated and 
on the nature of the particular compound which is being used. 
22 
ile composition comprising a compound of the invention, in a 
unit dosage form in a sealed container. The compound or salt 
is provided in the form of a lyophilizate which is capable of 
being reconstituted with a suitable pharmaceutically accept-
able carrier to form a liquid composition suitable for injection 
thereof into a subject. The unit dosage form typically com-
prises from about 10 mg to about 10 grams of the compound 
or salt. When the compound or salt is substantially water-
insoluble, a sufficient amount of emulsifying agent which is 
10 pharmaceutically acceptable can be employed in sufficient 
quantity to emulsify the compound or salt in an aqueous 
carrier. One such useful emulsifying agent is phosphatidyl 
choline. 
In some embodiments, it may be desirable to deliver the 
formulation locally to avoid any side effects associated with 
systemic administration. For example, local administration 
can be accomplished by direct injection at the desired treat-
ment site, by introduction intravenously at a site near a 
desired treatment site (e.g., into a vessel that feeds a treatment 15 
site). In certain embodiments, the formulation can be a slow 
release formulation, e.g., in the form of a slow release depot. 
Formulations suitable for rectal administration are prefer-
ably presented as unit dose suppositories. These can be pre-
pared by admixing the compound with one or more conven-
tional solid carriers, for example, cocoa butter, and then 
shaping the resulting mixture. For injection, the carrier will typically be a liquid, such as 
sterile pyrogen-free water, pyrogen-free phosphate-buffered 
saline solution, bacteriostatic water, or Cremophor EL[R] 20 
(BASF, Parsippany, N.J.). For other methods of administra-
tion, the carrier can be either solid or liquid. 
Formulations suitable for topical application to the skin 
preferably take the form of an ointment, cream, lotion, paste, 
gel, spray, aerosol, or oil. Carriers which can be used include 
petroleum jelly, lanoline, polyethylene glycols, alcohols, 
transdermal enhancers, and combinations of two or more 
thereof. 
For oral administration, the compound can be administered 
in solid dosage forms, such as capsules, tablets, and powders, 
or in liquid dosage forms, such as elixirs, syrups, and suspen- 25 
sions. Compounds can be encapsulated in gelatin capsules 
together with inactive ingredients and powdered carriers, 
such as glucose, lactose, sucrose, mannitol, starch, cellulose 
Formulations suitable for transdermal administration can 
be presented as discrete patches adapted to remain in intimate 
contact with the epidermis of the recipient for a prolonged 
period of time. Formulations suitable for transdermal admin-
istration can also be delivered by iontophoresis (see, for 
example, Tyle, Pharm. Res. 3:318 (1986)) and typically take 
the form of an optionally buffered aqueous solution of the 
or cellulose derivatives, magnesium stearate, stearic acid, 
sodium saccharin, talcum, magnesium carbonate and the like. 30 
Examples of additional inactive ingredients that can be added 
to provide desirable color, taste, stability, buffering capacity, 
dispersion or other known desirable features are red iron 
oxide, silica gel, sodium lauryl sulfate, titanium dioxide, 
edible white ink and the like. Similar diluents can be used to 35 
compound. Suitable formulations comprise citrate or bis\tris 
buffer (pH 6) or ethanol/water and contain from 0.1 to 0.2M 
of the compound. 
The compound can alternatively be formulated for nasal 
make compressed tablets. Both tablets and capsules can be 
manufactured as sustained release products to provide for 
continuous release of medication over a period of hours. 
Compressed tablets can be sugar coated or film coated to 
mask any unpleasant taste and protect the tablet from the 
atmosphere, or enteric-coated for selective disintegration in 
the gastrointestinal tract. Liquid dosage forms for oral admin-
istration can contain coloring and flavoring to increase patient 
acceptance. 
Formulations suitable for buccal (sub-lingual) administra-
tion include lozenges comprising the compound in a flavored 
base, usually sucrose and acacia or tragacanth; and pastilles 
comprising the compound in an inert base such as gelatin and 
glycerin or sucrose and acacia. 
Formulations of the present invention suitable for 
parenteral administration comprise sterile aqueous and non-
aqueous injection solutions of the one or more miRNAs or 
vectors, which preparations are preferably isotonic with the 
blood of the intended recipient. These preparations can con-
tain anti-oxidants, buffers, bacteriostats and solutes which 
renderthe formulation isotonic with the blood of the intended 
recipient. Aqueous and non-aqueous sterile suspensions can 
include suspending agents and thickening agents. The formu-
lations can be presented in unit/dose or multi-dose containers, 
for example sealed ampoules and vials, and can be stored in a 
freeze-dried (lyophilized) condition requiring only the addi-
tion of the sterile liquid carrier, for example, saline or water-
for-injection immediately prior to use. 
Extemporaneous injection solutions and suspensions can 
be prepared from sterile powders, granules and tablets of the 
kind previously described. For example, in one aspect of the 
present invention, there is provided an injectable, stable, ster-
administration or otherwise administered to the lungs of a 
subject by any suitable means, e.g., administered by an aero-
sol suspension of respirable particles comprising the com-
pound, which the subject inhales. The respirable particles can 
40 be liquid or solid. The term "aerosol" includes any gas-borne 
suspended phase, which is capable of being inhaled into the 
bronchioles or nasal passages. Specifically, aerosol includes a 
gas-borne suspension of droplets, as can be produced in a 
metered dose inhaler or nebulizer, or in a mist sprayer. Aero-
45 sol also includes a dry powder composition suspended in air 
or other carrier gas, which can be delivered by insufflation 
from an inhaler device, for example. See Ganderton & Jones, 
Drug Delivery to the Respiratory Tract, Ellis Horwood 
(1987); Gonda (1990) Critical Reviews in Therapeutic Drug 
50 Carrier Systems 6:273-313; and Rae burn et al., J. Pharmacol. 
Toxicol. Meth. 27:143 (1992). Aerosols of liquid particles 
comprising the compound can be produced by any suitable 
means, such as with a pressure-driven aerosol nebulizer or an 
ultrasonic nebulizer, as is known to those of skill in the art. 
55 See, e.g., U.S. Pat. No. 4,501,729. Aerosols of solid particles 
comprising the compound can likewise be produced with any 
solid particulate medicament aerosol generator, by tech-
niques known in the pharmaceutical art. 
Alternatively, one can administer the compound in a local 
60 rather than systemic marmer, for example, in a depot or sus-
tained-release formulation. 
Further, the present invention provides liposomal formula-
tions of the compounds disclosed herein and salts thereof. 
The technology for forming liposomal suspensions is well 
65 known in the art. When the compound or salt thereof is an 
aqueous-soluble salt, using conventional liposome technol-
ogy, the same can be incorporated into lipid vesicles. In such 
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an instance, due to the water solubility of the compound or 
salt, the compound or salt will be substantially entrained 
within the hydrophilic center or core of the liposomes. The 
lipid layer employed can be of any conventional composition 
and can either contain cholesterol or can be cholesterol-free. 5 
2010/0057 41, which describes a crosslinked polymer particle 
comprising the active agent non-covalently associated with 
the nanogel. In representative embodiments, the crosslinked 
polymer particle comprises poly(N-isopropylmethacryla-
mide) and N,N'-methylenebis(acrylamide). In particular 
embodiments, the nanogel further comprises a cross-linked 
polymer shell comprising a functionalization agent, wherein 
the crosslinked polymer shell is disposed substantially 
around the crosslinked polymer particle. According to this 
When the compound or salt of interest is water-insoluble, 
again employing conventional liposome formation technol-
ogy, the salt can be substantially entrained within the hydro-
phobic lipid bilayer which forms the structure of the lipo-
some. In either instance, the liposomes which are produced 
can be reduced in size, as through the use of standard sonica-
tion and homogenization techniques. 
In a representative embodiment, a polynucleotide can be 
entrapped in a lipid particle bearing positive charges on its 
surface and, optionally, tagged with antibodies against cell 
surface antigens of the target tissue (Mizuno et al., No Shinkei 
Geka 20:547 (1992); PCT publication WO 91/06309; Japa-
nese patent application 1047381; and European patent pub-
lication EP-A-43075). Exemplary targeting moieties are as 
described elsewhere herein. 
Liposomes that consist of amphiphilic cationic molecules 
are useful as non-viral vectors for nucleic acid delivery in 
vitro and in vivo (reviewed in Crystal, Science 270:404 
(1995); Blaese eta!., Cancer Gene Ther. 2:291 (1995); Behret 
al., Bioconjugate Chem. 5:382 (1994); Remy et al., Biocon-
jugate Chem. 5:647 (1994); and Gao et al., Gene Therapy 
2:710 (1995) ). The positively charged liposomes are believed 
to complex with negatively charged nucleic acids via electro-
static interactions to form lipid:nucleic acid complexes. The 
lipid:nucleic acid complexes have several advantages as 
nucleic acid transfer vectors. Unlike viral vectors, the lipid: 
nucleic acid complexes can be used to transfer expression 
cassettes of essentially unlimited size. Since the complexes 
lack proteins, they can evoke fewer immunogenic and inflam-
matory responses. Moreover, they cannot replicate or recom-
bine to form an infectious agent and have low integration 
frequency. A number of publications have demonstrated that 
amphiphilic cationic lipids can mediate nucleic acid delivery 
in vivo and in vitro (Feigner et al., Proc. Natl. Acad. Sci. USA 
84:7413 (1987); Loeffler et al., Meth. Enzymol. 217:599 
(1993); Feigner et al., J. Biol. Chem. 269:2550 (1994)). 
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embodiment, the crosslinked polymer shell can comprise, 
without limitation, poly(N-isopropylmethacrylamide ), N,N'-
methylenebis( acrylamide) and aminopropylmethacrylamide. 
The nanogel can further comprise a targeting moiety, as 
15 described elsewhere herein. 
In particular embodiments, the compound is administered 
to the subject in a treatment effective amount, as that term is 
defined herein. Dosages of pharmaceutically active com-
pounds can be determined by methods known in the art, see, 
20 e.g., Remington's Pharmaceutical Sciences (Maack Publish-
ing Co., Easton, Pa.). The therapeutically effective dosage of 
any specific compound will vary somewhat from compound 
to compound, and patient to patient, and will depend upon the 
condition of the patient and the route of delivery. As a general 
25 proposition, a dosage from about 0.1 to about 50 mg/kg will 
have therapeutic efficacy, with all weights being calculated 
based upon the weight of the compound, including the cases 
where a salt is employed. Toxicity concerns at the higher level 
can restrict intravenous dosages to a lower level such as up to 
30 about 10 mg/kg, with all weights being calculated based upon 
the weight of the compound, including the cases where a salt 
is employed. A dosage from about 10 mg/kg to about 50 
mg/kg can be employed for oral administration. Typically, a 
dosage from about 0.5 mg/kg to 5 mg/kg can be employed for 
35 intramuscular injection. Particular dosages are about 1 µmo!/ 
kg to 50 µmol/kg, and more particularly to about 22 µmo I/kg 
and to 33 µmol/kg of the compound for intravenous or oral 
administration, respectively. 
The present invention is more particularly described in the 
40 following examples that are intended as illustrative only since 
numerous modifications and variations therein will be appar-
ent to those skilled in the art. Several groups have reported the use of amphiphilic cat-
ionic lipid:nucleic acid complexes for in vivo transfection 
both in animals and in humans (reviewed in Gao et al., Gene 
Therapy 2:710 (1995); Zhu et al., Science 261:209 (1993); 45 
and Thierry et al., Proc. Natl. Acad. Sci. USA 92:9742 
(1995)). U.S. Pat. No. 6,410,049 describes a method of pre-
paring cationic lipid:nucleic acid complexes that have a pro-
longed shelflife. 
Example 1 
Materials and Methods 
Cell Lines. 
The OVCAR3 cell line was originally established from the 
ascites of a patient with poorly differentiated papillary epi-
thelial OC [Hamilton et al., Cancer Res 1985, 45:3668-76]. 
The liposomal formulations comprising the compounds 50 
disclosed herein or salts thereof, can be lyophilized to pro-
duce a lyophilizate which can be reconstituted with a phar-
maceutically acceptable carrier, such as water, to regenerate a 
liposomal suspension. 
miRNAs, polynucleotides, nucleic acids, vectors and the 55 
like can also be delivered to a cell in vitro, ex vivo or in vivo 
using nanoparticle delivery systems (e.g., a nano gel). Exem-
plary nanoparticles include, but are not limited to, nano-
spheres (including polymer nanospheres), microspheres (in-
cluding polymer micelles), dendrimers, quantum dots, gold 60 
nanoshells, nanocrystals, colloidal gold, nanoemulsions, 
nanogels, silver nanoparticles, silica nanoparticles, and the 
like. 
The OVCAR3 cell line was obtained from the American Type 
Culture Collection (Manassas, Va.). The HEY cell line was 
derived from a patient with moderately differentiated papil-
lary cystadenocarcinoma of the ovary [Buick et al., Cancer 
Res 1985, 45:3668-76]. The HEY cell line was kindly pro-
vided by Gordon Mills, Department of Molecular Therapeu-
tics, University of Texas, MD Anderson Cancer Center. 
microRNA Transfection. 
6xl04 cells per well were seededin24-well plates.After 24 
h, cells were transfected with 30 nM of miR-429 andmiR-320 
miRNA oligonucleotides (Ambion, Austin, Tex.) using Lipo-
fectamine 2000 reagent (Invitrogen, Carlsbad, Calif.). The 
Ambion Pre-miRNA Precursor Negative Control was used as Suitable nano gels include hydrogels (e.g., hyaluronic acid 
nano gels), polyethylene glycol-polyethylenimine (PEG-PEI) 
nanogels, poly(alkylacrylamide) nanogels, and the like. 
Other illustrative nanogels include those disclosed in WO 
65 a control. Three days after transfection, cells were split and 
transfected again. This process was repeated every 3 days 
until 21 days when cells were assayed for response. 
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RNA Quantification. 
Total RNA was extracted from cells using the miRVana 
miRNA isolation kit (Ambion). MicroRNA expression was 
carried our using TaqMan microRNA assays (Applied Bio-
systems, Carlsbad, Calif.) with human U6 as the endogenous 5 
control. For mRNA quantitation, RNA ( 4.0 µg) was reversed 
transcribed into cDNA using the Superscript III First-strand 
Synthesis System (Invitrogen) according to the manufactur-
er's instructions using sequence specific primers. Real-time 
PCR was performed using Power SYBR Green PCR Master 10 
Mix (Bio-Rad, Hercules, Calif.) and data normalized to glyc-
eraldehydes-3-phosphate-dehydrogenase (GAPDH). Each 
transfection experiment was carried out in triplicate with 3 
PCR reactions performed per transfection. The PCR results 
were analyzed by 1-way Analysis of.Variance (ANOVA) and 15 
the Newman-Keuls-Student t test. A p value of <0.05 was 
considered significant. 
Microarray Analyses. 
Microarray analyses were performed using the Affymetrix 
system (HG-U133 Plus 2.0; Santa Clara, Calif.) as previously 20 
described [Bowen et al., BMC Med Genomics 2009, 2:71]. 
Briefly, the expression data were analyzed using MAS 5.0 
Statistical Algorithm encoded in the Affymetrix Expression 
Console application. The expression values were normalized 
across samples by Z-score calculation using Spotfire Deci- 25 
sion Site software. AN OVA was used to identify genes whose 
expression was significantly different (p<0.015; fold change 
;;,;l.5 or fold change 1.5) between HEY cells transfected with 
miR-429 and the negative control. Gene enrichment analyses 
were carried out using GeneGO (http://www.genego.com/) 30 
gene ontology software. 
Invasion, Migration, Wound Healing and Anchorage-Inde-
pendent Growth Assays. 
For the migration and invasion assays, 2.5xl03 overnight 
serum starved cells in serum-free media were added to the top 35 
chambers of trans-well plates (8 µm pore size; BD, Franklin 
Lakes, N.J.) and media containing 10% fetal calf serum 
(FCS) were added to the bottom chambers. After 8-12 h, the 
non-migrating (top) cells were removed and the invading 
(bottom) cells were counted. All assays were done in tripli- 40 
cate. For the wound-healing assay, 2.5xl 05 cells were seeded 
into six-well plates. After 24 h, a wound was incised, detached 
cells removed and fresh media added. Photos were taken after 
8 hrs to monitor the invasion of cells into the wounded area. 
26 
static than OVCAR3 cells in xenograft mouse models [Shaw 
et al., Mo! Ther 2004; 10:1032-42]. Consistent with these 
morphological distinctions, we found that the mesenchymal 
markers vimentin (VIM), fibronectin (FNl) and N-cadherin 
are all more highly expressed in HEY cells relative to 
OVCAR3 cells (FIG. lB). In addition, the epithelial marker, 
E-cadherin, is expressed at significantly lower levels while 
the repressors of E-cadherin, ZEB 1 and ZEB2, are expressed 
at significantly higher levels in HEY cells relative to 
OVCAR3 cells (FIG. lB). Consistent with the hypothesis that 
the down-regulation of members of the miRNA-200 family 
and miR-205 may contribute to EMT in ovarian cancer, we 
found that miR-141, miR-429 and miR-205 are all expressed 
at significantly lower levels in HEY cells relative to OVCAR3 
cells (p<0.01, FIG. lC). No significant changes were 
observed in levels oflet-7a, let-7d or mir-320 (p>0.01; FIG. 
lC). 
Example 3 
Overexpression ofmiR-429 in HEY Cells Induces 
Morphological and Molecular Changes Consistent 
with a Mesenchymal-to-Epithelial Transition (MET) 
To test the hypothesis that miR-200 family members may 
be involved in EMT in OC, we compared the effect of ectopic 
expression ofmiR-429 in HEY cells relative to miR-320 and 
a control RNA sequence not homologous to any known 
microRNA. While miR-320 expression is reported to have an 
inhibitory effect on cell proliferation [Schaar et al., Exp 
Hematol 2009; 37:245-55], it has not been previously impli-
cated in EMT. MiR-429 was selected to represent the miR-
200 family because it is predicted to have the largest number 
of putative target sites in ZEB! and ZEB2 mRNAs (ZEB! 
mRNA contains 5 putative biding sites for miR-429, 3 for 
miR-141 and 1 for miR-205; ZEB2 mRNA contains 6 puta-
tive binding sites for miR-429, 3 for miR-141 and 2 for 
miR-205). We reasoned that if down-regulation of miR-429 
contributes to EMT in OC, expression of miR-429 in the more 
mesenchymal-like HEY cells might be expected to induce 
changes characteristic of MET while expression of the con-
trol sequences should have little or no effect. 
The results presented in FIG. 2A demonstrate that expres-
sion of miR-429 induced HEY cells to undergo a morpho-
45 logical change from an elongated, spindle-shaped, mesen-
chymal phenotype to a more rounded, epithelial-like 
phenotype. In contrast, no change in morphology was 
detected in HEY cells transfected with miR-320 or with the 
Anchorage independent growth was examined using Cell 
Biolab's (San Diego, Calif.) soft agar kit according to the 
manufacturer's protocol. Briefly, 5,000 cells were grown in a 
0.3% low melting temperature agar matrix. After 8 days of 
incubation, the agar matrix was solubilized, cells stained and 
absorbancerecordedat 520 nm. The optical density (OD) was 50 
measured in a 96-well plate reader using a 485/520 nm filter 
set. 
Example 2 
OVCAR3 and HEY Cells Display Molecular Profiles 
Consistent with their Distinct Epithelial and 
Mesenchymal-Like Morphologies 
55 
To explore a possible role of microRNAs in ovarian cancer 60 
EMT and metastasis, we compared the expression levels of 2 
miR-200 family microRNAs (miR-141, miR-429), miR-205, 
let-7a, let-7d and miR-320 between two OC cell lines. 
OVCAR3 cells display a rounded/cobblestone, epithelial-like 
morphology while HEY cells display a more elongated mor- 65 
phology characteristic of mesenchymal cells (FIG. lA) and 
have been shown to be significantly more invasive and meta-
negative control microRNA sequence. Consistent with the 
miR-429 induced change in morphology, we observed a sig-
nificant decrease in levels of ZEB 1 and ZEB2 and a concomi-
tant increase in levels of E-cadherin (FIG. 2B). Again, no 
significant change was detected in cells transfected with miR-
320 or with the negative control microRNA. 
Example 4 
Overexpression ofmiR-429 in HEY Cells Induces 
Global Changes in Gene Expression Consistent with 
MET 
To more fully characterize the molecular effects of miR-
429 expression in HEY cells, we conducted a comparative 
microarray profiling analysis (Affymetrix HG-U133 Plus 
2.0). The results demonstrate that 296 genes were signifi-
cantly down regulated and 373 genes were significantly up 
regulated in the miR429-transfected cells compared with 
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controls (p<0.015; foldchange;;,;1.5 orfoldchange;;,;1.5; Table 
2). Included among those genes displaying significant 
changes in expression after miR-429 transfection were the 
mesenchymal markers ZEB 1 and VCAN (versican) [Solter-
mann et al, Clin Cancer Res 2008; 14:7430-7] (both down- 5 
regulated) and the epithelial markers TSPAN13 (tetraspanin-
13) [Huang et al., J Cancer Res Clin Oncol 2007; 133:761-9], 
CAV2 (caveolin 2) [Moreno-Bueno et al., Cancer Res 2006; 
66:9543-56], DSP (desmoplakin) [Sarri6 et al., Cancer Res 
2008; 68:989-97] and EPCAM (epithelial cell adhesion mo!- 10 
ecule) [Huang et al., Cancer Res 2007; 67:11147-57] (all 
up-regulated). While ZEB 2 was found to be significantly 
down regulated in our RT-PCR analysis, it did not display a 
significant change in expression in our microarray analysis. 15 
We attribute this inconsistency to the fact that microarray is 
less sensitive than RT-PCR in the detection of changes in low 
abundant transcripts [Meyer et al., Biotechniques 2004; 
36:618-20]. 
The fact that <9% of genes significantly down regulated in 20 
expression are predicted targets of miR-429 (3% predicted by 
Target Scan -http://www.targetscan.org/; 9% by miRanda 
-http://www.microrna.org/microrna/home.do) (Table 3) sug-
gests that the vast majority of the observed molecular changes 
were indirect effects of miR-429 over expression. Gene onto!- 25 
ogy (GO) analysis of the 669 genes displaying significant 
changes in expression in the miR-429 transfected cells dem-
onstrated a significant enrichment for genes associated with 
functions typically associated with EMT and metastasis (e.g., 
significant over-representation of genes involved in EMT, cell 30 
differentiation/development, cell junction and cell adhesion, 
FIG. 3 and Tables 4-6). 
28 
Collectively, our results are consistent with the hypothesis 
that miR-200 family microRNAs and miR-429, in particular, 
are directly involved in EMT and the promotion of OC 
metastasis. 
Example 6 
miR-429 Transfection Increases Sensitivity of HEY 
Cells to Cisplatin 
Cultures of the mesenchymal HEY cells were transfected 
with a negative control (NC) miRNA or miR-429 using Lipo-
fectamine 2000 (Invitrogen) and treated with increasing con-
centrations ofcisplatin. (0.1, 0.5, 1, 3, 5, 7, 10, 15, 20, 30, 50 
µM). Sensitivity to cisplatin increased significantly in the 
presence ofmiR-429 as compared with the negative control 
(FIG. 5; IC50 4.6 vs. 8.7 for experimental and control groups, 
respectively). 
Example 7 
Ectopic Expression ofmiR-200 Family in Animal 
Models of Ovarian Cancer 
A mouse model of ovarian cancer is used to evaluate the 
effectiveness of upregulation of miR-200 family members 
(miR-141, miR-200a, miR-200b, miR-200c, miR-205 and/or 
miR-429) altogether, individually or in combination (e.g., 
miR-200c/miR-141 or miR-200a/miR-200b/miR-429), for 
treatment of ovarian cancer as well as the ability to reduce 
metastasis (including malignant ascites) and/ or recurrence/ 
disease progression, to prolong progression-free survival 
and/or overall survival and/or to enhance sensitivity to che-
motherapy. One suitable mouse model is the mouse xenograft Example 5 
Overexpression ofmiR-429 in HEY Cells Induces 
Changes in Functional Characteristics Consistent 
with MET 
35 model in which human ovarian cancer cells are delivered 
subcutaneously or into the peritoneum of nude mice. Other 
models of ovarian cancer include a mouse model with con-
current homozygous knockout of p53 and Rb. Further, trans-
genic mice in which the 5' upstream regulatory sequences of 
40 the mouse misiir (Mullerian inhibitory substance type II 
To further explore the effects of ectopic expression of receptor) gene were used to target expression of the SV 40 
miR-429 in HEY cells, we looked for changes in cellular large T antigen (TAg) specifically to the female reproductive 
functions frequently associated with EMT. For example, ova- epithelium, developed ovarian carcinomas with metastatic 
rianandothertypes of cancer cells undergoingEMTtypically spread by three months of age (Vanderhyden et al., Animal 
display increased motility/migration and invasiveness. To 45 models of ovarian cancer. Reproductive Biology and Endo-
determine if expression of miR-429 resulted in a reduction in crinology 2003, 1 :67). 
the migratory ability oftransfected HEY cells, we monitored One or more miR-200 family members are transiently 
the effect of serum-induced migration of cells using chamber delivered by the intravenous or intraperitoneal route to two 
assays. The results demonstrate that miR-429 transfected groups of mice, while the other two groups receive a negative 
HEY cells migrated through pores >2-fold slower than the 50 control miRNA. Within the experimental and control treat-
negative controls (FIG. 4A). Relative invasiveness was also ments, one group will receive a chemotherapeutic agent (e.g., 
measured by monitoring serum-induced invasion through a a platinum drug and/or a taxane) 0, 24, 48 or 72 hours after 
matrigel layer. The results indicate a >5-fold decrease in administration of the miRNA(s) and one does not. Transient 
invasion in miR-429 transfected HEY cells relative to con- delivery of the miRNA(s) can be achieved by any suitable 
trols (FIG. 4A). The reduced migration of HEY cells over 55 means, e.g., by lipofection (see, Example 1) or by a targeted 
nano gel (see, e.g., Dickerson et al., BMC Cancer 2010, 10: 1 O; 
expressing miR-429 was further confirmed using the wound WO 20101005741 ). 
healing assay (FIG. 4B). The animals are monitored and evaluated for regression of 
Anchorage-independent growth is another characteristic of the tumors and/or extent of metastasis (including malignant 
mesenchymal cells and is considered a hallmark of cellular 60 ascites ), with and without chemotherapy. Animals showing a 
transformation [Takeyama et al., Cancer Lett 2010; 96:216- partial or complete response to treatment can be further moni-
24]. We tested anchorage-independent growth of HEY cells tared for recurrence/disease progression. Progression-free 
transfected with miR-429 relative to controls. After 8 days survival and/or overall survival can also be determined. 
incubation in soft agar, the miR-429 transfected cells dis- The foregoing is illustrative of the present invention, and is 
played a significant suppression of anchorage-independent 65 not to be construed as limiting thereof, The invention is 
growth relative to controls consistent with miR-429 induced defined by the following claims, with equivalents of the 
MET (FIG. 4C). claims to be included therein. 
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All publications, patent applications, patents and other ref-
erences cited herein are incorporated by reference in their 
entireties for the teachings relevant to the sentence and/or 
paragraph in which the reference is presented. 
TABLE2 
List of genes differentially expressed between miR-429 
and negative control micro RNA transfected HEY cells. 
Shown are fold changes and significance values. 
Gene Symbol 
LOC284561 
NOC2L 
PAPPA2 
COLEC12 
TLRl 
SNORA68 
PCOTH 
CDOl 
SYF2 
GAS7 
ALDH1L2 
SHANK2 
LOC286178 
HORMADl 
SLC24A3 
C12orf39 
LOC401497 
ANKRD23 
hCG_l654703 
LOC158381 
PSATl 
ASNS 
MARS 
SLC27A4 
C12orf55 
TMEM201 
SLC7All 
F2RL2 
SH3PXD2B 
GLT8D2 
PCK2 
NAV3 
OSTMl 
SLC1A4 
EPHBl 
CCND2 
CHSTlO 
GART 
PHGDH 
FOXP3 
PYGOl 
SESN2 
ANK2 
ERNl 
ABCF2 
ASAM 
CDC42EP1 
Cl 7orf51 
JDP2 
MGC16121 
CCDC148 
KIAA1853 
GRK4 
LM04 
HIF3A 
CCDC152 
PTPN13 
LOC148987 
MRAP 
MERTK 
SLC1A5 
BCHE 
RGMB 
EXOSC6 
GPATCH4 
INTS4 
Fold change (miR-429 
transfected HEY cells relative 
to negative controls 
-38.32 
-26.91 
-23.75 
-16.11 
-15.24 
-14.52 
-13.93 
-13.45 
-12.64 
-12.55 
-11.31 
-10.85 
-10.56 
-10.48 
-10.20 
-10.06 
-9.19 
-7.62 
-7.46 
-7.31 
-6.92 
-6.82 
-6.59 
-6.23 
-6.06 
-5.58 
-5.46 
-5.35 
-5.13 
-4.76 
-4.44 
-4.35 
-4.35 
-4.32 
-4.06 
-4.03 
-4.03 
-3.94 
-3.78 
-3.76 
-3.61 
-3.61 
-3.58 
-3.51 
-3.48 
-3.48 
-3.48 
-3.46 
-3.46 
-3.46 
-3.39 
-3.32 
-3.14 
-3.14 
-3.12 
-3.10 
-3.10 
-3.07 
-3.05 
-3.03 
-3.01 
-2.93 
-2.89 
-2.87 
-2.87 
-2.81 
p-value 
0.0010 
0.0083 
0.0008 
0.0010 
0.0101 
0.0129 
0.0035 
0.0008 
0.0020 
0.0035 
0.0041 
0.0084 
0.0115 
0.0005 
0.0003 
0.0010 
0.0002 
0.0077 
0.0139 
0.0136 
0.0021 
0.0029 
0.0081 
0.0024 
0.0100 
0.0082 
0.0018 
0.0030 
0.0065 
0.0148 
0.0004 
0.0050 
0.0025 
0.0048 
0.0039 
0.0001 
0.0041 
0.0076 
0.0115 
0.0044 
0.0009 
0.0085 
0.0032 
0.0035 
0.0058 
0.0042 
0.0076 
0.0139 
0.0015 
0.0008 
0.0054 
0.0023 
0.0022 
0.0081 
0.0147 
0.0054 
0.0021 
0.0079 
0.0031 
0.0139 
0.0055 
0.0080 
0.0139 
0.0001 
0.0028 
0.0093 
10 
15 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
30 
TABLE 2-continued 
List of genes differentially expressed between miR-429 
and negative control microRNA transfected HEY cells. 
Shown are fold changes and significance values. 
Gene Symbol 
CLGN 
TMEM156 
CYCS 
FLJ34077 
GLIPRl 
LOC148189 
CBS 
DDR2 
LRP4 
SYTll 
CDKALl 
HS6ST3 
ZNF30 
AARS 
CXCL3 
KLHL13 
SGSH 
MARS2 
C6orf105 
HSPA9 
LOC439949 
CCNJ 
PITX2 
RPL22Ll 
YARS 
SR CAP 
Cllorf57 
GALNT12 
Fold change (miR-429 
transfected HEY cells relative 
to negative controls 
-2.79 
-2.79 
-2.73 
-2.73 
-2.73 
-2.69 
-2.68 
-2.68 
-2.66 
-2.66 
-2.64 
-2.64 
-2.62 
-2.57 
-2.57 
-2.57 
-2.57 
-2.50 
-2.48 
-2.48 
-2.48 
-2.45 
-2.45 
-2.45 
-2.45 
-2.43 
-2.41 
-2.39 
TABLE3 
p-value 
0.0123 
0.0130 
0.0089 
0.0118 
0.0066 
0.0133 
0.0101 
0.0027 
0.0022 
0.0043 
0.0141 
0.0098 
0.0112 
0.0058 
0.0025 
0.0088 
0.0141 
0.0124 
0.0063 
0.0003 
0.0023 
0.0109 
0.0118 
0.0113 
0.0082 
0.0092 
0.0005 
0.0005 
Only -9% of genes down regulated in miR-429 transfected 
HEY cells are predicted targets ofmiR-429. (A) MiRanda 
predicted targets of miR-429 that were down regulated in miR-429 
transfected HEY cells (9% of all down regulated genes). (B) 
Targetscan predicted targets of miR-429 that were down 
regulated in miR-429 transfected HEY cells (3% of all down 
Gene 
ALDH1L2 
PSATl 
MARS 
NAV3 
OSTMl 
GART 
PTPN13 
BCHE 
GALNT12 
TIGDl 
TSGA14 
B3GALNT2 
EIF2B5 
GREMl 
RDHlO 
SHMT2 
ZNF697 
WDR43 
LOC339290 
ZBTB24 
STARD13 
ZEB! 
CFL2 
LDLRAD3 
VCAN 
DPY19Ll 
re ulated enes . 
Fold-change 
A 
-11.31 
-6.92 
-6.59 
-4.35 
-4.35 
-3.94 
-3.10 
-2.93 
-2.39 
-2.38 
-2.33 
-2.16 
-2.10 
-2.10 
-2.08 
-2.04 
-1.91 
-1.88 
-1.87 
-1.87 
-1.78 
-1.78 
-1.75 
-1.74 
-1.66 
-1.64 
t-test 
0.0041 
0.0021 
0.0081 
0.0050 
0.0025 
0.0076 
0.0021 
0.0080 
0.0005 
0.0006 
0.0075 
0.0005 
0.0086 
0.0055 
0.0133 
0.0001 
0.0114 
0.0125 
0.0114 
0.0145 
0.0040 
0.0018 
0.0142 
0.0063 
0.0135 
0.0033 
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TABLE 3-continued TABLE 4-continued 
Only -9% of genes down regulated in miR-429 transfected Differentially expressed genes displaying significant enrichment 
HEY cells are predicted targets ofmiR-429. (A) MiRanda in the GO (gene ontology) classification "cellular components" 
predicted targets ofmiR-429 that were down regulated in miR-429 between miR-429 and negative control microRNA transfected 
transfected HEY cells (9% of all down regulated genes). (B) HEY cells. 
Targetscan predicted targets ofmiR-429 that were down 
regulated in miR-429 transfected HEY cells (3% of all down GO classification 
re ulated enes. (cellular components) gene name enrichment P value 
Gene Fold-change t-test Cell junction LPP 2.232E-2 
10 Cell junction MAP3Kl 2.232E-2 
PRTG -1.61 0.0043 Cell junction NEDD9 2.232E-2 
DNAJB4 -1.53 0.0081 Cell junction OXTR 2.232E-2 
B Cell junction PPP1R9B 2.232E-2 
Cell junction PTK2B 2.232E-2 
OSTMl -4.35 0.0025 Cell junction SHANK2 2.232E-2 
TSGA14 -2.33 0.0075 15 Cell junction SIPA!Ll 2.232E-2 
EIF2B5 -2.10 0.0086 Cell junction SORBSl 2.232E-2 
RDHlO -2.08 0.0133 Cell junction SYNGAPl 2.232E-2 
ZNF697 -1.91 0.0114 Cell junction SYNM 2.232E-2 
SENP5 -1.80 0.0007 Cell junction SYT12 2.232E-2 
STARD13 -1.78 0.0040 
Cell junction TJP2 2.232E-2 
Cell junction WASF2 2.232E-2 
ZEB! -1.78 0.0018 20 Cell-substrate junction BAIAP2 2.458E-2 
CFL2 -1.75 0.0142 Cell-substrate junction DST 2.458E-2 
DPY19Ll -1.64 0.0033 Cell-substrate junction ENAH 2.458E-2 
Cell-substrate junction ETY4 2.458E-2 
Cell-substrate junction FYN 2.458E-2 
Cell-substrate junction LAMA3 2.458E-2 
TABLE4 25 Cell-substrate junction LPP 2.458E-2 
Cell-substrate junction NEDD9 2.458E-2 
Differentially expressed genes displaying significant enrichment Cell-substrate junction PTK2B 2.458E-2 
in the GO (gene ontology) classification "cellular components" Cell-substrate junction SORBSl 2.458E-2 
between miR-429 and negative control micro RNA transfected Cell-substrate junction WASF2 2.458E-2 
HEY cells. Larninin-1 complex LAMA3 2.502E-2 
30 Larninin-1 complex LAMA4 2.502E-2 
GO classification Larninin-1 complex SDC2 2.502E-2 
(cellular components) gene name enrichment P value Larninin-1 complex SLPI 2.502E-2 
Cell-cell adherens junction DSP 3.073E-2 
Adherens junction ARHGEF12 3.485E-3 Cell-cell adherens junction LAMA3 3.073E-2 
Adherens junction ARHGEF2 3.485E-3 Cell-cell adherens junction OXTR 3.073E-2 
Adherens junction BAIAP2 3.485E-3 35 Cell-cell adherens junction PLEKHA7 3.073E-2 
Adherens junction ENAH 3.485E-3 Cell-cell adherens junction SORBSl 3.073E-2 
Adherens junction ETY4 3.485E-3 Extracellular matrix ADAMTS12 3.928E-2 
Adherens junction FYN 3.485E-3 Extracellular matrix ADAMTS18 3.928E-2 
Adherens junction LAMA3 3.485E-3 Extracellular matrix ANGPTL4 3.928E-2 
Adherens junction LPP 3.485E-3 Extracellular matrix COL13Al 3.928E-2 
Adherens junction NEDD9 3.485E-3 Extracellular matrix COL6Al 3.928E-2 
Adherens junction OXTR 3.485E-3 40 Extracellular matrix DMPl 3.928E-2 
Adherens junction PPP1R9B 3.485E-3 Extracellular matrix DSPP 3.928E-2 
Adherens junction PTK2B 3.485E-3 Extracellular matrix DST 3.928E-2 
Adherens junction SORBSl 3.485E-3 Extracellular matrix F3 3.928E-2 
Adherens junction SYNM 3.485E-3 Extracellular matrix FYN 3.928E-2 
Adherens junction TJP2 3.485E-3 Extracellular matrix HBEGF 3.928E-2 
Adherens junction WASF2 3.485E-3 45 Extracellular matrix IGFBP3 3.928E-2 
Cell-cell junction ARHGEF2 5.254E-3 Extracellular matrix KLK2 3.928E-2 
Cell-cell junction B4GALT1 5.254E-3 Extracellular matrix LAMA3 3.928E-2 
Cell-cell junction BYES 5.254E-3 Extracellular matrix LAMA4 3.928E-2 
Cell-cell junction CDC42BPA 5.254E-3 Extracellular matrix LMCDl 3.928E-2 
Cell-cell junction COL13Al 5.254E-3 Extracellular matrix MAP3Kl 3.928E-2 
Cell-cell junction FMNL2 5.254E-3 50 Extracellular matrix MMPl 3.928E-2 
Cell-cell junction INADL 5.254E-3 Extracellular matrix PLAT 3.928E-2 
Cell-cell junction LAMA3 5.254E-3 Extracellular matrix SDC2 3.928E-2 
Cell-cell junction OXTR 5.254E-3 Extracellular matrix SLPI 3.928E-2 
Cell-cell junction SORBSl 5.254E-3 Extracellular matrix SPINT2 3.928E-2 
Cell-cell junction TJP2 5.254E-3 Extracellular matrix TGFB2 3.928E-2 
Cell junction ARHGEF12 2.232E-2 55 Extracellular matrix THBSl 3.928E-2 
Cell junction ARHGEF2 2.232E-2 Extracellular matrix YCAN 3.928E-2 
Cell junction B4GALT1 2.232E-2 Cytoskeleton AKAP12 4.656E-2 
Cell junction BAIAP2 2.232E-2 Cytoskeleton ANK2 4.656E-2 
Cell junction BYES 2.232E-2 Cytoskeleton ANXAll 4.656E-2 
Cell junction CDC42BPA 2.232E-2 Cytoskeleton ARHGEF12 4.656E-2 
Cell junction COL13Al 2.232E-2 Cytoskeleton ARHGEF2 4.656E-2 
Cell junction DNMBP 2.232E-2 60 Cytoskeleton ARRBl 4.656E-2 
Cell junction DST 2.232E-2 Cytoskeleton BAIAP2 4.656E-2 
Cell junction ENAH 2.232E-2 Cytoskeleton BR!Pl 4.656E-2 
Cell junction ETY4 2.232E-2 Cytoskeleton BYSL 4.656E-2 
Cell junction FYN 2.232E-2 Cytoskeleton C13orf15 4.656E-2 
Cell junction INADL 2.232E-2 Cytoskeleton C21orf33 4.656E-2 
Cell junction LAMA3 2.232E-2 65 Cytoskeleton CALM! 4.656E-2 
Cell junction LIMA! 2.232E-2 Cytoskeleton CAPG 4.656E-2 
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TABLE 4-continued 
Differentially expressed genes displaying significant enrichment 
in the GO (gene ontology) classification "cellular components" 
between miR-429 and negative control micro RNA transfected 
GO classification 
(cellular components) 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Cytoskeleton 
Focal adhesion 
Focal adhesion 
Focal adhesion 
Focal adhesion 
Focal adhesion 
Focal adhesion 
Focal adhesion 
Focal adhesion 
Focal adhesion 
Focal adhesion 
Focal adhesion 
HEY cells. 
gene name 
CASP9 
CFL2 
CLIC5 
CSRP3 
CYCS 
DCTNl 
DNM3 
DNMBP 
DSP 
DST 
DUSPl 
ENAH 
ERNl 
FGD4 
FMNL2 
FNBPl 
FYN 
GAS7 
GPR4 
H2AFY 
HIP! 
KIF2A 
KIT LG 
LIMA! 
LITAF 
MAP3Kl 
MTUSl 
MY06 
MY07A 
MYOF 
NDRGl 
NEDD9 
PLCG2 
PLEKHAl 
PLEKHA2 
PPP1R9B 
PROCR 
PTPN13 
PTPN14 
RASSF5 
SlOOA8 
SlOOA9 
SHANK2 
SIPA!Ll 
SLC1A4 
SLC7All 
SORBSl 
SPTBNl 
SYNM 
UACA 
WASF2 
WIPF2 
ARHGEF12 
BAIAP2 
ENAH 
ETV4 
FYN 
LPP 
NEDD9 
PDPKl 
PTK2B 
SORBSl 
WASF2 
enrichment P value 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
4.656E-2 
8.487E-2 
8.487E-2 
8.487E-2 
8.487E-2 
8.487E-2 
8.487E-2 
8.487E-2 
8.487E-2 
8.487E-2 
8.487E-2 
8.487E-2 
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TABLES 
Differentially expressed genes displaying significant 
enrichment in the GO classification "biological process" 
between miR-429 and negative control micro RNA 
transfected HEY cells. 
GO classification (biological process) gene name 
cell projection organization MY07A 
anatomical structure development GLI3 
1 o anatomical structure development LRP4 
cell differentiation AMH 
cell differentiation ANGPTL4 
cell differentiation CLGN 
cell differentiation COL13Al 
cell differentiation CSRP3 
15 cell differentiation DLXl 
cell differentiation DSPP 
cell differentiation ECSCR 
cell differentiation EFNA5 
cell differentiation ELF3 
cell differentiation EPAS 1 
cell differentiation ETV6 
20 cell differentiation FNBPl 
cell differentiation FZD5 
cell differentiation GADD45B 
cell differentiation GAS7 
cell differentiation HIP! 
cell differentiation KDM3A 
25 cell differentiation KIF2A 
cell differentiation L1 CAM 
cell differentiation NRPl 
cell differentiation PAPPA2 
cell differentiation PPP1R9B 
cell differentiation PSME4 
30 cell differentiation PTK2B 
cell differentiation SEMA5A 
cell differentiation SH3PXD2B 
cell differentiation SIM! 
cell differentiation SOX9 
cell differentiation SRRM4 
35 multicellular organismal development ANGPTL4 
multicellular organismal development ATR 
multicellular organismal development B3GNT5 
multicellular organismal development BSTl 
multicellular organismal development BYES 
multicellular organismal development CELSR2 
multicellular organismal development CLGN 
4o multicellular organismal development COL13Al 
multicellular organismal development CSRP3 
multicellular organismal development DLXl 
multicellular organismal development DSPP 
multicellular organismal development ECSCR 
multicellular organismal development EFNA5 
45 multicellular organismal development ELF3 
multicellular organismal development EPAS 1 
multicellular organismal development FNBPl 
multicellular organismal development FYN 
multicellular organismal development FZD5 
multicellular organismal development GADD45B 
50 multicellular organismal development GAS7 
multicellular organismal development GREMl 
multicellular organismal development HOXA13 
multicellular organismal development KIF2A 
multicellular organismal development KLF3 
multicellular organismal development L1 CAM 
55 multicellular organismal development LIMDl 
multicellular organismal development LSM14A 
multicellular organismal development NRPl 
multicellular organismal development PIM! 
multicellular organismal development PITX2 
multicellular organismal development PPP1R9B 
multicellular organismal development PRTG 
60 multicellular organismal development PSME4 
multicellular organismal development SEMA5A 
multicellular organismal development SIM! 
multicellular organismal development SORLl 
multicellular organismal development VCAN 
multicellular organismal development WLS 
65 multicellular organismal development ZNF260 
enrichment P value 
3.748E-13 
4.258E-12 
4.258E-12 
2.040E-11 
2.040E-11 
2.040E-11 
2.040E-11 
2.040E-11 
2.040E-11 
2.040E-11 
2.040E-11 
2.040E-11 
2.040E-11 
2.040E-11 
2.040E-11 
2.040E-11 
2.040E-11 
2.040E-11 
2.040E-11 
2.040E-11 
2.040E-11 
2.040E-11 
2.040E-11 
2.040E-11 
2.040E-11 
2.040E-11 
2.040E-11 
2.040E-11 
2.040E-11 
2.040E-11 
2.040E-11 
2.040E-11 
2.040E-11 
6.012E-11 
6.012E-11 
6.012E-11 
6.012E-11 
6.012E-11 
6.012E-11 
6.012E-11 
6.012E-11 
6.012E-11 
6.012E-11 
6.012E-11 
6.012E-11 
6.012E-11 
6.012E-11 
6.012E-11 
6.012E-11 
6.012E-11 
6.012E-11 
6.012E-11 
6.012E-11 
6.012E-11 
6.012E-11 
6.012E-11 
6.012E-11 
6.012E-11 
6.012E-11 
6.012E-11 
6.012E-11 
6.012E-11 
6.012E-11 
6.012E-11 
6.012E-11 
6.012E-11 
6.012E-11 
6.012E-11 
6.012E-11 
6.012E-11 
6.012E-11 
6.012E-11 
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TABLE6 TABLE 6-continued 
Differentially expressed genes displaying significant Differentially expressed genes displaying significant 
enrichment in the GO classification "biological process enrichment in the GO classification "biological process 
network" between miR-429 and negative control network" between miR-429 and negative control 
microRNA transfected HEY cells. micro RNA transfected HEY cells. 
enrichment enrichment 
GO classification (process network) gene name P value GO classification (process network) gene name P value 
Cell adbesion_Synaptic contact BAIAP2 5.045E-05 rearrangement 
Cell adbesion_Synaptic contact CNTNl 5.045E-05 10 Cytoskeleton_Regulation of cytoskeleton CDC42BPA 4.046E-02 
Cell adbesion_Synaptic contact EFNA5 5.045E-05 rearrangement 
Cell adbesion_Synaptic contact EPHBl 5.045E-05 Cytoskeleton_Regulation of cytoskeleton CFL2 4.046E-02 
Cell adbesion_Synaptic contact EPHB2 5.045E-05 rearrangement 
Cell adbesion_Synaptic contact FYN 5.045E-05 Cytoskeleton_Regulation of cytoskeleton DST 4.046E-02 
Cell adbesion_Synaptic contact LlCAM 5.045E-05 rearrangement 
Cell adbesion_Synaptic contact NCAMl 5.045E-05 15 Cytoskeleton_Regulation of cytoskeleton FGD4 4.046E-02 
Cell adbesion_Synaptic contact NLGN3 5.045E-05 rearrangement 
Cell adbesion_Synaptic contact SDC2 5.045E-05 Cytoskeleton_Regulation of cytoskeleton NEDD9 4.046E-02 
Cell adbesion_Synaptic contact SHANK2 5.045E-05 rearrangement 
Cell adbesion_Synaptic contact SYNGAPl 5.045E-05 Cytoskeleton_Regulation of cytoskeleton PREXl 4.046E-02 
Cell adbesion_Synaptic contact SYTll 5.045E-05 rearrangement 
Cell adbesion_Synaptic contact SYT12 5.045E-05 Cytoskeleton_Regulation of cytoskeleton SPTBNl 4.046E-02 
Cell adbesion_Synaptic contact YWHAH 5.045E-05 20 rearrangement 
Cell adbesion_Attractive and repulsive ARHGEF12 7.846E-04 Cytoskeleton_Regulation of cytoskeleton WASF2 4.046E-02 
receptors rearrangement 
Cell adbesion_Attractive and repulsive CFL2 7.846E-04 Cytoskeleton_Regulation of cytoskeleton YWHAH 4.046E-02 
receptors rearrangement 
Cell adbesion_Attractive and repulsive COL13Al 7.846E-04 Development_Neurogenesis:Axonal ARHGEF12 1.365E-05 
receptors 25 guidance/Synaptogenesis 
Cell adbesion_Attractive and repulsive EFNA5 7.846E-04 Development_Neurogenesis:Axonal BAIAP2 1.365E-05 
receptors guidance/Synaptogenesis 
Cell adbesion_Attractive and repulsive ENAH 7.846E-04 Development_Neurogenesis:Axonal CALM! 1.365E-05 
receptors guidance/Synaptogenesis 
Cell adbesion_Attractive and repulsive EPHBl 7.846E-04 Development_Neurogenesis:Axonal CFL2 1.365E-05 
receptors 30 guidance/Synaptogenesis 
Cell adbesion_Attractive and repulsive EPHB2 7.846E-04 Development_Neurogenesis:Axonal DCTNl 1.365E-05 
receptors guidance/Synaptogenesis 
Cell adbesion_Attractive and repulsive FYN 7.846E-04 Development_Neurogenesis:Axonal DPYSL3 1.365E-05 
receptors guidance/Synaptogenesis 
Cell adbesion_Attractive and repulsive LlCAM 7.846E-04 Development_Neurogenesis:Axonal EFNA5 1.365E-05 
receptors 35 guidance/Synaptogenesis 
Cell adbesion_Attractive and repulsive NCAMl 7.846E-04 Development_Neurogenesis:Axonal ENAH 1.365E-05 
receptors guidance/Synaptogenesis 
Cell adbesion_Attractive and repulsive NEOl 7.846E-04 Development_Neurogenesis:Axonal EPHBl 1.365E-05 
receptors guidance/Synaptogenesis 
Cell adbesion_Attractive and repulsive NRPl 7.846E-04 Development_Neurogenesis:Axonal EPHB2 1.365E-05 
receptors 
40 
guidance/Synaptogenesis 
Cell adbesion_Attractive and repulsive RAS Al 7.846E-04 Development_Neurogenesis:Axonal FYN 1.365E-05 
receptors guidance/Synaptogenesis 
Cell adbesion_Attractive and repulsive SEMA5A 7.846E-04 Development_Neurogenesis:Axonal GAS7 1.365E-05 
receptors guidance/Synaptogenesis 
Cell adhesion_Leucocyte chemotaxis ARHGEF12 6.066E-04 Development_Neurogenesis:Axonal LlCAM 1.365E-05 
Cell adhesion_Leucocyte chemotaxis CALM! 6.066E-04 guidance/Synaptogenesis 
Cell adhesion_Leucocyte chemotaxis CFL2 6.066E-04 45 Development_Neurogenesis:Axonal NCAMl 1.365E-05 
Cell adhesion_Leucocyte chemotaxis CXCL2 6.066E-04 guidance/Synaptogenesis 
Cell adhesion_Leucocyte chemotaxis CXCL3 6.066E-04 Development_Neurogenesis:Axonal NEOl 1.365E-05 
Cell adhesion_Leucocyte chemotaxis CYTH3 6.066E-04 guidance/Synaptogenesis 
Cell adhesion_Leucocyte chemotaxis F2RL2 6.066E-04 Development_Neurogenesis:Axonal NRPl 1.365E-05 
Cell adhesion_Leucocyte chemotaxis FYN 6.066E-04 guidance/Synaptogenesis 
Cell adhesion_Leucocyte chemotaxis ITGA9 6.066E-04 50 Development_Neurogenesis:Axonal PLCG2 1.365E-05 
Cell adhesion_Leucocyte chemotaxis LPARl 6.066E-04 guidance/Synaptogenesis 
Cell adhesion_Leucocyte chemotaxis LPAR3 6.066E-04 Development_Neurogenesis:Axonal SDC2 1.365E-05 
Cell adhesion_Leucocyte chemotaxis OXTR 6.066E-04 guidance/Synaptogenesis 
Cell adhesion_Leucocyte chemotaxis PDPKl 6.066E-04 Development_Neurogenesis:Axonal SEMA5A 1.365E-05 
Cell adhesion_Leucocyte chemotaxis PLCG2 6.066E-04 guidance/Synaptogenesis 
Cell adhesion_Leucocyte chemotaxis PTK2B 6.066E-04 55 Development_Neurogenesis:Axonal WASF2 1.365E-05 
Cell adhesion_Leucocyte chemotaxis RASSF5 6.066E-04 guidance/Synaptogenesis 
Cytoskeleton_Actin filaments CAPG 3.132E-02 Development_Neurogenesis:Axonal YWHAH 1.365E-05 
Cytoskeleton_Actin filaments CDC42BPA 3.132E-02 guidance/Synaptogenesis 
Cytoskeleton_Actin filaments CFL2 3.132E-02 Development_Blood vessel morphogenesis ANGPTL4 3.074E-04 
Cytoskeleton_Actin filaments DCTNl 3.132E-02 Development_Blood vessel morphogenesis EDNl 3.074E-04 
Cytoskeleton_Actin filaments DST 3.132E-02 Development_Blood vessel morphogenesis EGLNl 3.074E-04 
Cytoskeleton_Actin filaments FYN 3.132E-02 60 Development_Blood vessel morphogenesis EPASl 3.074E-04 
Cytoskeleton_Actin filaments MYOlD 3.132E-02 Development_Blood vessel morphogenesis F2RL2 3.074E-04 
Cytoskeleton_Actin filaments MY06 3.132E-02 Development_Blood vessel morphogenesis FGFRl 3.074E-04 
Cytoskeleton_Actin filaments MY07A 3.132E-02 Development_Blood vessel morphogenesis FOXFl 3.074E-04 
Cytoskeleton_Actin filaments NEDD9 3.132E-02 Development_Blood vessel morphogenesis HBEGF 3.074E-04 
Cytoskeleton_Actin filaments SPTBNl 3.132E-02 Development_Blood vessel morphogenesis KLK2 3.074E-04 
Cytoskeleton_Actin filaments WASF2 3.132E-02 65 Development_Blood vessel morphogenesis LlCAM 3.074E-04 
Cytoskeleton_Regulation of cytoskeleton ARHGEF2 4.046E-02 Development_Blood vessel morphogenesis LPARl 3.074E-04 
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TABLE 6-continued TABLE 6-continued 
Differentially expressed genes displaying significant 
enrichment in the GO classification "biological process 
network" between miR-429 and negative control 
microRNA transfected HEY cells. 
Differentially expressed genes displaying significant 
enrichment in the GO classification "biological process 
network" between miR-429 and negative control 
micro RNA transfected HEY cells. 
enrichment 
GO classification (process network) gene name P value GO classification (process network) 
Development_Blood vessel morphogenesis LPAR3 3.074E-04 Development_Regulation of angiogenesis 
Development_Blood vessel morphogenesis MAP3Kl 3.074E-04 10 Development_Regulation of angiogenesis 
Development_Blood vessel morphogenesis NRPl 3.074E-04 Development_Regulation of angiogenesis 
Development_Blood vessel morphogenesis OXTR 3.074E-04 Development_Regulation of angiogenesis 
Development_Blood vessel morphogenesis PDElC 3.074E-04 Development_Regulation of angiogenesis 
Development_Blood vessel morphogenesis PDPKl 3.074E-04 Development_Regulation of angiogenesis 
Development_Blood vessel morphogenesis PITX2 3.074E-04 Development_Regulation of angiogenesis 
Development_Blood vessel morphogenesis PG Kl 3.074E-04 
Development_Blood vessel morphogenesis PLAT 3.074E-04 
Development_Regulation of angiogenesis 
Development_Regulation of angiogenesis 
15 
Development_Blood vessel morphogenesis TGFA 3.074E-04 Development_Regulation of angiogenesis 
Development_Regulation of angiogenesis ANGPTL4 6.241E-04 Development_Regulation of angiogenesis 
Development_Regulation of angiogenesis EDNl 6.241E-04 Development_Regulation of angiogenesis 
Development_Regulation of angiogenesis EFNA5 6.241E-04 Development_Regulation of angiogenesis 
Development_Regulation of angiogenesis EPHBl 6.241E-04 
Development_Regulation of angiogenesis EPHB2 6.241E-04 
Development_Regulation of angiogenesis 
20 
SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS, 11 
<210> SEQ ID NO 1 
<211> LENGTH, 95 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 1 
ccagcucggg cagccguggc caucuuacug ggcagcauug gauggaguca ggucucuaau 60 
acugccuggu aaugaugacg gcggagcccu gcacg 95 
<210> SEQ ID NO 2 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 2 
uaauacugcc ugguaaugau ga 
<210> SEQ ID NO 3 
<211> LENGTH, 68 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 3 
22 
cccucgucuu acccagcagu guuugggugc gguugggagu cucuaauacu gccggguaau 60 
gauggagg 68 
<210> SEQ ID NO 4 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 4 
uaauacugcc ggguaaugau gga 
<210> SEQ ID NO 5 
<211> LENGTH, 83 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
23 
enrichment 
gene name P value 
F2RL2 6.241E-04 
GLI3 6.241E-04 
GLMN 6.241E-04 
HBEGF 6.241E-04 
MALT! 6.241E-04 
OXTR 6.241E-04 
PDPKl 6.241E-04 
PITX2 6.241E-04 
RASAl 6.241E-04 
SEMA5A 6.241E-04 
TGFB2 6.241E-04 
TGFBRl 6.241E-04 
THBSl 6.241E-04 
ZEB! 6.241E-04 
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-continued 
<400> SEQUENCE, 5 
cgccggccga ugggcgucuu accagacaug guuagaccug gcccucuguc uaauacuguc 60 
ugguaaaacc guccauccgc ugc 83 
<210> SEQ ID NO 6 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 
uaauacuguc ugguaaaacc gu 
<210> SEQ ID NO 7 
<211> LENGTH, 95 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 7 
22 
cggccggccc uggguccauc uuccaguaca guguuggaug gucuaauugu gaagcuccua 60 
acacugucug guaaagaugg cucccgggug gguuc 95 
<210> SEQ ID NO 8 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 8 
uaacacuguc ugguaaagau gg 
<210> SEQ ID NO 9 
<211> LENGTH, 90 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 9 
22 
ccgggccccu gugagcaucu uaccggacag ugcuggauuu cccagcuuga cucuaacacu 60 
gucugguaac gauguucaaa ggugacccgc 90 
<210> SEQ ID NO 10 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 10 
uaacacuguc ugguaacgau gu 
<210> SEQ ID NO 11 
<211> LENGTH, 13 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, EphA2 receptor targeting sequence 
<400> SEQUENCE, 11 
Tyr Ser Ala Tyr Pro Asp Ser Val Pro Met Met Ser Cys 
1 5 10 
22 
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We claim: 
1. A method of sensitizing an ovarian cancer to a cytotoxic 
therapy, the method comprising delivering a modified miR-
429, wherein the modified miR-429 comprises a seed 
sequence, AAUACUG, and further wherein the modified 
65 miR-429 comprises one or more nucleotide substitutions and/ 
or deletions in the nucleotide sequence of SEQ ID N0:5 
outside of the seed sequence, to a mammalian subject in need 
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thereof in an amount effective to sensitize the ovarian cancer 
to cytotoxic therapy. 
2. The method of claim 1, wherein the method further 
comprises detecting a level of one or more miR-200 family 
members in ovarian cancer tissue from the subject that is 5 
below a reference value prior to administering the modified 
miR-429 to the subject. 
3. The method of claim 1, wherein the method further 
comprises detecting cells having a mesenchymal phenotype 
in ovarian cancer tissue from the subject prior to administer- 10 
ing the modified miR-429 to the subject. 
4. The method of claim 1, wherein the method further 
comprises administering a cytotoxic therapy prior to, concur-
rently with and/or after administration of the modified miR- 15 
429. 
5. The method of claim 4, wherein the cytotoxic therapy 
comprises a chemotherapy agent. 
6. The method of claim 4, wherein the cytotoxic therapy 
comprises radiation therapy. 20 
7. The method of claim 1, wherein the modifiedmiR-429 is 
transiently delivered by lipofection, a nanoparticle delivery 
system, or a nanogel delivery system. 
42 
8. The method of claim 7, wherein the method comprises 
administration of a nano gel delivering the modified miR-429 
to the subject, wherein the nanogel comprises a crosslinked 
polymer particle comprising the active agent non-covalently 
associated with the nanogel. 
9. The method of claim 8, wherein the crosslinked polymer 
particle comprises poly(N-isopropylmethacrylamide) and 
N,N'-methy lenebis( a cry !amide). 
10. The method of claim 8, wherein the nanogel further 
comprises a cross-linked polymer shell, wherein the 
crosslinked polymer shell is disposed substantially around 
the crosslinked polymer particle. 
11. The method of claim 10, wherein the crosslinked poly-
mer shell comprises poly(N-isopropylmethacrylamide), 
N,N'-methy lenebis( a cry !amide), and aminopropy lmethacry-
lamide. 
12. The method of claim 1, wherein a mature modified 
miR-429 is administered to the subject. 
13. The method of claim 1, wherein a human modified 
miR-429 is delivered. 
14. The method of claim 1, wherein the subject is a human 
subject. 
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